Alessandra Ferrajoli, MD

Peer-Reviewed Articles

1. Kim E, Chen SS, Sivina M, Hwang H, Huang X, Ferrajoli A, Jain N, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood None(None):None, 2024. PMID: 39441901.
2. Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, Konopleva M, Wierda W, Huang X, Maiti A, Issa G, Balkin H, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Kantarjian HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia None(None):None, 2024. PMID: 39322712.
3. Nebgen DR, Cheng L, Alousi AM, Ferrajoli A. Decreased Transfusions in Premenopausal Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation Given Leuprolide According to an Abnormal Uterine Bleeding Algorithm. JCO Oncol Pract None(None):OP2400169, 2024. PMID: 39284100.
4. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma 65(9):1325-1334, 2024. PMID: 38749022.
5. Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, Hammond D, Swaminathan M, Jain N, Wierda W, Ferrajoli A, DiNardo C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematol None(None):1-10, 2024. PMID: 38861934.
6. Hampel, PJ, Swaminathan, M, Rogers, KA, Parry, EM, Burger, JA, Davids, MS, Ding, W, Ferrajoli, A, Hyak, JM, Jain, N, Kenderian, S, Wang, Y, Wierda, WG, Woyach, JA, Parikh, SA, Thompson, PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Advances 8(10):2342-2350, 2024. PMID: 38537065.
7. Braish J, Cerchione C, Ferrajoli A. An Overview of Prognostic Markers in Patients with CLL. Frontiers in Oncology 14, 2024. PMID: None.
8. Kang, DW, Wang, L, Short, NJ, Ferrajoli, A, Wang, Y, Zhou, S, Shen, C. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. PharmacoEconomics 42(4):409-418, 2024. PMID: 38184494.
9. Lee CY, Gordon MJ, Markofski MM, LaVoy EC, Peterson SK, Li L, Fares S, Baum M, Pace M, Walsh D, Ferrajoli A, Basen-Engquist K. Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study. J Cancer Survivor, 2024. PMID: 38472612.
10. Gordon, MJ, Duan, Z, Zhao, H, Nastoupil, L, Iyer, S, Ferrajoli, A, Danilov, AV, Giordano, SH. Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma. JCO Clinical Cancer Informatics 8, 2024. PMID: 38684043.
11. Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
12. Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol 34(9):796-805, 2023. e-Pub 2023. PMID: 37414216.
13. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma 64(9):1554-1561, 2023. e-Pub 2023. PMID: 37317991.
14. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
15. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
16. Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ferrajoli A, Danilov AV, Giordano SH. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv 7(11):2632-2642, 2023. e-Pub 2023. PMID: 36753602.
17. Crane JC, Gordon MJ, Basen-Engquist K, Ferrajoli A, Markofski MM, Lee CY, Fares S, Simpson RJ, LaVoy EC. Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. Eur J Haematol 110(6):732-742, 2023. e-Pub 2023. PMID: 36946440.
18. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
19. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2022. PMID: 36287248.
20. McGhie A, Lee J, Ferrajoli A, DiPippo AJ. Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. Leuk Lymphoma 64(5):1050-1053, 2023. e-Pub 2023. PMID: 36891585.
21. Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):1-4, 2023. e-Pub 2023. PMID: 36657414.
22. Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovic M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Österborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol 41(5):JCO2200510, 2023. e-Pub 2022. PMID: 36395435.
23. Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 388(4):319-332, 2023. e-Pub 2022. PMID: 36511784.
24. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
25. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
26. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
27. Brown, JR, Hillmen, P, Eichhorst, B, Lamanna, N, O'Brien, S, Tam, CS, Qiu, LG, Kazmierczak, M, Zhou, K, Šimkovič, M, Mayer, J, Gillespie-Twardy, A, Shadman, M, Ferrajoli, A, Ganly, P, Weinkove, R, Salmi, T, Wu, K, Novotny, WF, Jurczak, W. CLL-115 First Interim Analysis of ALPINE Study. Clinical Lymphoma, Myeloma and Leukemia 22:S266, 2022. PMID: 36163869.
28. Rozovski, U, Veletik, I, Harris, D, Li, P, Liu, Z, Jain, P, Manshouri, T, Ferrajoli, A, Burger, JA, Bose, P, Thompson, PA, Jain, N, Wierda, WG, Verstovsek, S, Keating, M, Estrov, Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clinical Lymphoma, Myeloma and Leukemia 22:S271, 2022. PMID: 36163878.
29. Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
30. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
31. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 107(6):1335-1346, 2022. e-Pub 2022. PMID: 34587719.
32. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
33. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
34. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):885-893, 2022. PMID: 35225133.
35. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2021. PMID: 34668451.
36. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J 12(3):43, 2022. e-Pub 2022. PMID: 35301276.
37. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Kantarjian HM, Keating MJ, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24):2589-2592, 2021. e-Pub 2021. PMID: 34521099.
38. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
39. Esposito CL, Van Roosbroeck K, Santamaria G, Rotoli D, Sandomenico A, Wierda WG, Ferrajoli A, Ruvo M, Calin GA, de Franciscis V, Catuogno S. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. Cancers (Basel) 13(20):5220, 2021. e-Pub 2021. PMID: 34680368.
40. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 35(9):2621-2634, 2021. e-Pub 2021. PMID: 33654205.
41. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
42. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. PMID: 34110383.
43. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
44. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
45. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
46. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2020. PMID: 33087831.
47. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
48. Samra, B, Kantarjian, HM, Sasaki, K, Alotaibi, AS, Konopleva, M, O'Brien, S, Ferrajoli, A, Garris, R, Nunez, CA, Kadia, TM, Short, NJ, Jabbour, EJ. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta haematologica 144(3):285-292, 2021. PMID: 33238261.
49. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1-10, 2021. e-Pub 2020. PMID: 33327833.
50. Slager SL, Lanasa MC, Marti GE, Achenbach SJ, Camp NJ, Abbasi F, Kay NE, Vachon CM, Cerhan JR, Johnston JB, Call TG, Rabe KG, Kleinstern G, Boddicker NJ, Norman AD, Parikh SA, Leis JF, Banerji V, Brander DM, Glenn M, Ferrajoli A, Curtin K, Braggio E, Shanafelt TD, McMaster ML, Weinberg JB, Hanson CA, Caporaso NE. Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families. Blood 137(15):2046-2056, 2021. e-Pub 2020. PMID: 33512457.
51. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
52. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
53. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
54. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
55. Hwang JP, Ferrajoli A, Lok AS. Hepatitis B reactivation after chemoimmunotherapy: screen before treatment. Lancet 397(10273):510, 2021. PMID: 33549195.
56. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
57. Siddiqui, MT, Price, A, Ferrajoli, A, Borthakur, G. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax. Leukemia Research Reports 16, 2021. PMID: 34692401.
58. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk ET, Hwang JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2020. PMID: 32314052.
59. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
60. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia. Am J Hematol 95(10):1127 - 1134, 2020. e-Pub 2020. PMID: 32557828.
61. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. PMID: 32946567.
62. Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445. e-Pub 2020. PMID: 32937250.
63. Vaisitti T, Arruga F, Ferrajoli A. Chronic Lymphocytic Leukemia. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32899284.
64. Vitale C, Ferrajoli A. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. Expert Rev Hematol:1-10. e-Pub 2020. PMID: 32700593.
65. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. e-Pub 2020. PMID: 32546726.
66. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2019. PMID: 31862959.
67. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
68. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
69. Liu H, Miao Y, Ferrajoli A, Tang G, McDonnell T, Medeiros LJ, Hu S. Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy. Am J Hematol. e-Pub 2020. PMID: 32162729.
70. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
71. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma 61(2):1-5, 2020. e-Pub 2019. PMID: 31566032.
72. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
73. Terracciano D, Buonerba C, Scafuri L, De Berardinis P, Calin GA, Ferrajoli A, Fabbri M, Cimmino A. Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic. Front Oncol 10:1556, 2020. e-Pub 2020. PMID: 32984015.
74. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
75. Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol 20(11):1576-1586, 2019. e-Pub 2019. PMID: 31582354.
76. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
77. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. PMID: 31537528.
78. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther 12(3):161-165, 2019. e-Pub 2017. PMID: 28830803.
79. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
80. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. e-Pub 2019. PMID: 31344256.
81. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. e-Pub 2019. PMID: 31243771.
82. Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli A. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma 60(6):1568-1571, 2019. e-Pub 2019. PMID: 30632839.
83. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
84. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31248056.
85. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
86. Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson P, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA. miRNAs involvement in the pathogenesis of Richter's syndrome. Haematologica 104(5):1004-1015, 2019. e-Pub 2018. PMID: 30409799.
87. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2018. PMID: 30406944.
88. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
89. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
90. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. e-Pub 2019. PMID: 31005650.
91. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME. Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol 36(10):959-967, 2019. e-Pub 2018. PMID: 29447061.
92. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
93. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2018. PMID: 30508305.
94. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma:1-7. e-Pub 2019. PMID: 30773968.
95. Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(2):1-3, 2019. e-Pub 2018. PMID: 29911929.
96. Vitale C, Ferrajoli A. Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. Haematologica 104(1):9-12, 2019. PMID: 30598495.
97. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
98. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59(11):2686-2691, 2018. e-Pub 2018. PMID: 29465264.
99. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
100. Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP. Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematol 5(10):e474-e478, 2018. PMID: 30290904.
101. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. PMID: 30304652.
102. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
103. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
104. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
105. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39. e-Pub 2018. PMID: 30071517.
106. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
107. Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, Ramondetta L, Parker SL, Suarez-Almazor ME, Ferrajoli A, Shih YT, Giordano SH, Chiao EY. Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24(5):1094-1098, 2018. e-Pub 2018. PMID: 29378304.
108. Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk 18(5):e191-e195, 2018. e-Pub 2018. PMID: 29550108.
109. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
110. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32(4):960-970, 2018. e-Pub 2017. PMID: 28972595.
111. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
112. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2017. PMID: 29266206.
113. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180(4):597-600, 2018. e-Pub 2016. PMID: 27766619.
114. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
115. Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med 215(2):681-697, 2018. e-Pub 2018. PMID: 29301866.
116. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
117. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
118. Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 2(None):None, 2018. PMID: 31080940.
119. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyuz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology 7(4):e1417720, 2018. PMID: 29632735.
120. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer 123(24):4851-4859, 2017. e-Pub 2017. PMID: 28841236.
121. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):494-496, 2017. e-Pub 2017. PMID: 28798068.
122. Issa GC, Kantarjian H, Nogueras Gonzalez G, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
123. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
124. Ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfo L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia. Haematologica 102(10):394-396, 2017. e-Pub 2017. PMID: 28751563.
125. Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123(17):3367-3376, 2017. e-Pub 2017. PMID: 28518219.
126. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
127. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther 10(3):151-154, 2017. e-Pub 2016. PMID: 27352257.
128. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma 58(9):1-6, 2017. e-Pub 2017. PMID: 28278723.
129. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554-1559, 2017. PMID: 28379307.
130. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Vannini I, Redis RS, D'Abundo L, Zhang X, Xiao L, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2016. PMID: 27903673.
131. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
132. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
133. Fuentes-Mattei E, Giza DE, Shimizu M, Ivan C, Manning JT, Tudor S, Ciccone M, Kargin OA, Zhang X, Mur P, do Amaral NS, Chen M, Tarrand JJ, Lupu F, Ferrajoli A, Keating MJ, Vasilescu C, Yeung SJ, Calin GA. Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine 20:182-192, 2017. e-Pub 2017. PMID: 28465156.
134. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res 23(9):2154-2158, 2017. e-Pub 2016. PMID: 27797975.
135. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
136. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. PMID: 27655665.
137. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2016. PMID: 28003274.
138. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol 198(4):1740-1747, 2017. e-Pub 2017. PMID: 28077600.
139. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2016. PMID: 27763690.
140. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
141. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904, 2017. e-Pub 2017. PMID: 28138560.
142. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2016. PMID: 27595282.
143. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8(None):1773, 2017. PMID: 29379494.
144. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol 197(6):2522-31, 2016. e-Pub 2016. PMID: 27534555.
145. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 48:1-5, 2016. e-Pub 2016. PMID: 27416326.
146. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760-6, 2016. e-Pub 2016. PMID: 27301277.
147. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
148. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
149. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 101(6):e254-8, 2016. e-Pub 2016. PMID: 27013651.
150. Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda WG, Ferrajoli A. Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia. Ann Oncol 27(6):1100-6, 2016. e-Pub 2016. PMID: 26912560.
151. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 196(10):4400-9, 2016. e-Pub 2016. PMID: 27076684.
152. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation Between Responses and Immune Characteristics. Clin Cancer Res 22(1):1078-0432, 2016. e-Pub 2016. PMID: 26733610.
153. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2015. PMID: 26796981.
154. Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol 9(3):235-44, 2016. e-Pub 2016. PMID: 26652692.
155. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2015. PMID: 26588193.
156. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia 30(2):325-30, 2016. e-Pub 2015. PMID: 26290497.
157. Vitale C, Ferrajoli A. Richter Syndrome in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 11(1):43-51, 2016. PMID: 26830086.
158. Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(12):3452-4, 2015. e-Pub 2015. PMID: 25926060.
159. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
160. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer 121(21):3869-76, 2015. e-Pub 2015. PMID: 26218678.
161. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894-904, 2015. e-Pub 2015. PMID: 26217876.
162. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. e-Pub 2015. PMID: 26492205.
163. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
164. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
165. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170(1):125-8, 2015. e-Pub 2014. PMID: 25522014.
166. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
167. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-2382, 2015. e-Pub 2015. PMID: 25809968.
168. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with Chronic Lymphocytic Leukemia who received frontline FCR therapy - Distribution and clinical outcomes. Leuk Lymphoma 56(6):1-28, 2015. e-Pub 2014. PMID: 25308294.
169. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A Phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1-9, 2015. e-Pub 2014. PMID: 25311497.
170. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High FISH percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol 90(6):471-7, 2015. e-Pub 2015. PMID: 25683856.
171. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine 2(6):572-82, 2015. e-Pub 2015. PMID: 26288818.
172. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
173. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma 56(5):1-4, 2015. e-Pub 2014. PMID: 25120050.
174. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
175. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2014. PMID: 25312977.
176. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125(13):2062-7, 2015. e-Pub 2015. PMID: 25573991.
177. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. e-Pub 2015. PMID: 25824652.
178. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int 2015(None):497597, 2015. PMID: 25654108.
179. Vitale C, Hinojosa C, Keating J M, Pemmaraju N, O’Brien S, Wierda G W, Thomas H D, Borthakur G, Ohanian M, Burger A J, Ferrajoli A. Ofatumumab as front – line treatment in elderly unfit patients with chronic lymphocytic leukemia. Blood 124(21), 2014. PMID: None.
180. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 120(22):3494-501, 2014. e-Pub 2014. PMID: 25043749.
181. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 124(20):3059-64, 2014. e-Pub 2014. PMID: 25281606.
182. Ciccone M, Ferrajoli A, Keating MJ, Calin GA. SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell 26(5):770-770.e1, 2014. e-Pub 2014. PMID: 25517752.
183. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonzalez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. PMID: 25150798.
184. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. e-Pub 2014. PMID: 25042398.
185. Challagundla P, Jorgensen JL, Kanagal-Shamanna R, Gurevich I, Pierson DM, Ferrajoli A, Reyes SR, Medeiros LJ, Miranda RN. Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms. Arch Pathol Lab Med 138(7):903-9, 2014. PMID: 24978916.
186. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
187. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 2014. e-Pub 2013. PMID: 24440659.
188. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
189. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Mol Cancer Res. e-Pub 2014. PMID: 24836891.
190. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 123(18):2783-90, 2014. e-Pub 2014. PMID: 24615780.
191. Strati P, Keating MJ, O' Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. e-Pub 2014. PMID: 24859876.
192. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2013. PMID: 24332214.
193. Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2013. PMID: 23808813.
194. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 32(9):897-904, 2014. e-Pub 2014. PMID: 24516016.
195. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
196. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
197. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122(11):1891-9, 2013. e-Pub 2013. PMID: 23821659.
198. Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer 119(17):3177-85, 2013. e-Pub 2013. PMID: 24022787.
199. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system (CNS) Richter's transformation and parvovirus B19 infection. Leuk Lymphoma 54(9):2070-2, 2013. e-Pub 2013. PMID: 23320889.
200. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 2013. e-Pub 2013. PMID: 23701251.
201. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
202. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
203. Rozovski U, Calin GA, Setoyama T, D Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12(1):50. e-Pub 2013. PMID: 23725032.
204. Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O'Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV. Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genotypes. J Mol Diagn 15(2):196-209, 2013. e-Pub 2012. PMID: 23273604.
205. Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma. e-Pub 2013. PMID: 23163595.
206. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 31(5):584-91, 2013. e-Pub 2012. PMID: 23270003.
207. Faiz SA, Bashoura L, Lei X, Sampat KR, Brown TC, Eapen GA, Morice RC, Ferrajoli A, Jimenez CA. Pleural Effusions in Patients with Acute Leukemia and Myelodysplastic Syndrome. Leuk Lymphoma 54(2):329-335, 2013. e-Pub 2012. PMID: 22812422.
208. Ferrajoli A. Interfering with CD40 Ligation: A Sensitive Matter in Chronic Lymphocytic Leukemia. Leuk Lymphoma 53(11):2093-2094, 2012. e-Pub 2012. PMID: 22563816.
209. Coombs CC, Falchi L, Weinberg JB, Ferrajoli A, Lanasa MC. Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma 53(11):2326-9, 2012. e-Pub 2012. PMID: 22646816.
210. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 2012. e-Pub 2012. PMID: 22282348.
211. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. Single-nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood 120(8):1687-90, 2012. e-Pub 2012. PMID: 22745306.
212. Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531-3537, 2012. e-Pub 2011. PMID: 22139735.
213. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-1583, 2012. e-Pub 2012. PMID: 22362000.
214. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 2012. e-Pub 2012. PMID: 22422826.
215. Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 53(3):417-423, 2012. e-Pub 2011. PMID: 21879809.
216. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 2011. e-Pub 2011. PMID: 21733558.
217. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-Positive acute lymphoblastic leukemia cells. Invest New Drugs 29(6):1206-1212, 2011. e-Pub 2010. PMID: 20533075.
218. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-95, 2011. e-Pub 2011. PMID: 21969505.
219. Kornblau SM, Qiu YH, Zhang N, Singh N, Faderl S, Ferrajoli A, York H, Qutub AA, Coombes KR, Watson DK. Abnormal expression of friend leukemia virus integration 1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 118(20):5604-12, 2011. e-Pub 2011. PMID: 21917756.
220. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 2011. e-Pub 2011. PMID: 21821712.
221. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-3498, 2011. e-Pub 2011. PMID: 21725050.
222. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999-4008, 2011. e-Pub 2011. PMID: 21858802.
223. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-2068, 2011. e-Pub 2011. PMID: 21750315.
224. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-2093, 2011. e-Pub 2011. PMID: 21670470.
225. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):355-60, 2011. PMID: 21816374.
226. Ferrajoli A, Keating MJ, O'Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 117(14):3182-3186, 2011. e-Pub 2011. PMID: 21246526.
227. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 117(14):3268-3275, 2011. e-Pub 2011. PMID: 21264831.
228. Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts over-all survival in untreated patients. Blood 117(15):4076-4084, 2011. e-Pub 2011. PMID: 21310924.
229. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 activates nuclear factor (NF)-{kappa}B in chronic lymphocytic leukemia cells. Mol Cancer Res 9(4):507-515, 2011. e-Pub 2011. PMID: 21364020.
230. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 2011. e-Pub 2011. PMID: 21245487.
231. Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome. Cancer 117(20):4679-4688. e-Pub 2011. PMID: 21455998.
232. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2011. PMID: 21454191.
233. Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. PLoS One 6(12):e28277, 2011. e-Pub 2011. PMID: 22194822.
234. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 2011. PMID: None.
235. Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 23(11):1518-1523, 2010. e-Pub 2010. PMID: 20657554.
236. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 2010. e-Pub 2010. PMID: 20466853.
237. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880-3890, 2010. e-Pub 2010. PMID: 20660823.
238. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72-82, 2010. e-Pub 2010. PMID: 20456355.
239. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10):2360-2365, 2010. e-Pub 2010. PMID: 20225334.
240. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852-63, 2010. e-Pub 2010. PMID: 20154216.
241. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 34(3):284-288, 2010. e-Pub 2009. PMID: 19646755.
242. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-393, 2010. e-Pub 2009. PMID: 19895616.
243. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-397, 2010. e-Pub 2009. PMID: 20008621.
244. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Leuk Lymphoma 115(14):2852-2863, 2010. PMID: 20017599.
245. Ferrajoli A. Treatment of younger patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010(None):82-9, 2010. PMID: 21239775.
246. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(16):3982, 2010. e-Pub 2010. PMID: 20564167.
247. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-30, 2009. PMID: 19805674.
248. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504-10, 2009. e-Pub 2008. PMID: 19075265.
249. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113(14):3168-3171, 2009. PMID: 19050308.
250. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504-510, 2009. PMID: 19075266.
251. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood 114(5):957-964, 2009. e-Pub 2009. PMID: 19414856.
252. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol 31(1):97-105, 2009. PMID: 18190591.
253. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27(10):1637-1643, 2009. PMID: 19224852.
254. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-78, 2009. e-Pub 2009. PMID: 20017599.
255. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-4539, 2009. e-Pub 2009. PMID: 19637351.
256. Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 50(3):514-516, 2009. PMID: 19347738.
257. Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23(3):457-466, 2009. PMID: 18987653.
258. Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CH, van Oers MH, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res 33(9):1276-1281, 2009. e-Pub 2008. PMID: 190271161.
259. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pieerce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23):5490-5498, 2009. e-Pub 2009. PMID: 19708032.
260. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27(28):4760-4766, 2009. PMID: 19720904.
261. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-5430, 2009. e-Pub 2009. PMID: None.
262. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-3841, 2009. e-Pub 2009. PMID: 19536902.
263. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, J-P I, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-695, 2008. PMID: 18398735.
264. Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O'Brien S, Koller CA, Bodey GP, Keating MJ. Multiple dose granulocyte macrophage-colony stimulating factor plus 23-valent polysaccharide pneumonococcal vaccine in patients with chronic lymphocytic leukemia: A prospective, randomized trial of safety and immunogenicity. Cancer 113(2):383-387, 2008. PMID: 18470901.
265. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112(6):1306-1312, 2008. e-Pub 2008. PMID: 18224667.
266. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infec Dis 46(7):69-71, 2008. PMID: 18444808.
267. Ferrajoli A, B-L L, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-5297, 2008. PMID: 18334676.
268. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-1645, 2008. PMID: 18565853.
269. Ferrajoli A, Wierda WG, Lapushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 80(4):296-298, 2008. PMID: 18182081.
270. Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 141(1):36-40, 2008. PMID: 18324964.
271. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Ricon VM, Frankel SR, Kantarjian HM. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-1066, 2008. PMID: 17962510.
272. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-2096, 2008. PMID: 18756533.
273. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. PMID: 18182662.
274. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myeloid leukemia cells. Cancer Res 67(23):11291-11299, 2007. PMID: 18056455.
275. Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O'Brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR. Identification and validation of biomarkers of IgVH mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain. J Mol Diagn 9(4):546-555, 2007. PMID: 17690214.
276. Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumin level is associated with cytomegalovrus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 110(11):2478-2483, 2007. PMID: 17960607.
277. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lynmphocytic leukmeia. Blood 109(11):4679-4685, 2007. PMID: 17299097.
278. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. PMID: 17917961.
279. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 2007. PMID: 16882708.
280. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-3218, 2007. PMID: 17209054.
281. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leuk Res 31(7):939-945, 2007. PMID: 17045649.
282. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-627, 2007. PMID: 17223919.
283. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at The University of Texas, M. D. Anderson Cancer Center. J Clin Oncol 25(29):4648-4656, 2007. PMID: 17925562.
284. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase I study of Ionafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110(6):1295-1302, 2007. PMID: 17623836.
285. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31(1):91-5, 2007. PMID: 16828865.
286. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012-2018, 2007. PMID: 17849460.
287. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165-5173, 2006. PMID: 16951235.
288. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia trated with fludarabine-based regimens. Cancer 106(2):337-345, 2006. PMID: 16353201.
289. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer 107(5):925-934, 2006. PMID: 16832815.
290. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12):2645-2651, 2006. PMID: 16688777.
291. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization Proposal. Cancer 106(6):1306-1315, 2006. PMID: 16463391.
292. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients >=50 years. Blood 108(1):45-51, 2006. PMID: 16403905.
293. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M. D. Anderson Cancer Center. Blood 107(3):880-884, 2006. PMID: 16123215.
294. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'Brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(4):58-60, 2006. PMID: 16803568.
295. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30(7):813-822, 2006. PMID: 16478631.
296. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 30(3):362-363, 2006. PMID: 16168477.
297. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Kating MJ, Kantarjian HM. Eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL). Blood 107(12):4658-4662, 2006. PMID: 16497968.
298. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9):3469-3473, 2006. PMID: 16373661.
299. Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106(13):4303-4307, 2005. PMID: 16123221.
300. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-239, 2005. PMID: 16354329.
301. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-6624, 2005. PMID: 16166440.
302. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-2812, 2005. PMID: 15728224.
303. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 25(3):1841-1850, 2005. PMID: 16158916.
304. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-652, 2005. PMID: 15863204.
305. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 2005. PMID: 15767647.
306. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-7824, 2005. PMID: 16278404.
307. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-947, 2005. PMID: 15486072.
308. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873-2878, 2004. PMID: 15070658.
309. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-2917, 2004. PMID: 15131024.
310. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-589, 2004. PMID: 14745876.
311. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1):68-75, 2004. PMID: 14734453.
312. Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review o M. D. Anderson Cancer Center experience. Amer J Hematol 77(3):209-214, 2004. PMID: 15495258.
313. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-2591, 2004. PMID: 15197800.
314. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125(2):187-195, 2004. PMID: 15059141.
315. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104(6):1624-1630, 2004. PMID: 15178574.
316. Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology 9(4):279-286, 2004. PMID: 15621735.
317. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714-4716, 2003. PMID: 12595304.
318. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-2228, 2003. PMID: 12712475.
319. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52(6):449-452, 2003. PMID: None.
320. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12):3010-3016, 2003. PMID: 12784336.
321. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-1113, 2003. PMID: 12973833.
322. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-1103, 2003. PMID: 12764375.
323. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-3415, 2003. PMID: 12522009.
324. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21(9):1722-1727, 2003. PMID: 12721247.
325. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636-2642, 2003. PMID: 14669283.
326. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10):3794-3800, 2003. PMID: 12560227.
327. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98(4):773-778, 2003. PMID: 12910522.
328. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12):2657-2663, 2003. PMID: 14669286.
329. Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97(1):114-120, 2003. PMID: 12491512.
330. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97(4):1033-1041, 2003. PMID: 12569603.
331. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102(1):83-86, 2003. PMID: 12637317.
332. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9(3):976-980, 2003. PMID: 12631595.
333. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-1720, 2003. PMID: 12655528.
334. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100(4):1215-1219, 2002. PMID: 12149200.
335. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7(4):795-799, 2001. PMID: 11309324.
336. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma 30(3-4):279-292, 1998. PMID: 9713960.
337. Ferrajoli A, Liberati AM, Caricchi P, Donti E, Morra E, Lazzarino M, Betti AR, Bernasconi P, Saglio G. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. Eur J Haematol 55(3):184-188, 1995. PMID: 7672091.
338. Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov Z. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia 8(5):798-805, 1994. PMID: 8182937.
339. Liberati AM, Horisberger MA, Garofani P, De Angelis V, Ferrajoli A, Di Clemente F, Caricchi P, Adiuto D, Fedeli L, Palumbo B. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia. J Interferon Res 14(6):349-355, 1994. PMID: 7897254.
340. Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z. Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells 12(6):638-649, 1994. PMID: 7533582.
341. Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov Z. Growth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol 67(6):277-284, 1993. PMID: 7506581.
342. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia 7(2):214-220, 1993. PMID: 8426475.
343. Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells 11(2):112-119, 1993. PMID: 8384506.
344. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79(8):1938-1945, 1992. PMID: 1373331.
345. Liberati AM, Schippa M, Portuesi MG, Grazia Proietti M, De Angelis V, Ferrajoli A, Cinieri S, Di Clemente F, Palmisano L, Berruto P. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients. Haematologica 76(5):375-382, 1991. PMID: 1806440.
346. Liberati AM, Cinieri S, Senatore MG, Portuesi MG, De Angelis V, Di Clemente F, Schippa M, Ferrajoli A, Arzano S, Berruto P. Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma. Haematologica 75(5):436-442, 1990. PMID: 2129033.

Invited Articles

1. Al-Ameri A, Al-Kali A, Ferrajoli A. The role of monoclonal antibodies in the management of leukemia. Pharmaceuticals 3(10):3258-3274, 2010. PMID: None.
2. Ferrajoli A. Emerging strategies for eradicating minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL). Review. CLL: The Cutting Edge, 2007. PMID: None.
3. Ferrajoli A. Curing chronic lymphocytic leukemia. Foundations of Clinical Cancer Research 5(1):20-23, 2007. PMID: None.
4. Tam CS, Ferrajoli A, Keating MJ. Practical considerations for frontline therapy of chronic lymphocytic leukemia. Chron Lympho Leu 11(2):3-6, 2006. PMID: None.
5. Ferrajoli A, Faderl S, Keating MJ. Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 6(9):1231-1238, 2006. PMID: None.
6. Ferrajoli A. Acute myeloid leukemia in the elderly: A unique disease. Oncology 20(13):1684-1687, 2006. PMID: None.
7. Ferrajoli A. Expert Commentary: The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 107(4):773-780, 2006. PMID: None.
8. Ferrajoli A. Bendamustine in relapsed or refractory chronic lymphocytic leukemia. Haematologica 90(10):1300, 2005. PMID: 16219556.
9. Ferrajoli A, O'Brien SM. Treatment of chronic lymphocytic leukemia. Semin Oncol 31(2 (suppl.4)):60-65, 2004. PMID: 15124136.
10. Ferrajoli A, Keating MJ. Current guidelines in defining therapeutic strategies. Hematol Oncol Clin North Am 18(4):881-893, 2004. PMID: 15325704.
11. Ferrajoli A. Current guidelines in defining therapeutic strategies. Hematol Oncol Clin North Am 18(4):881-883, 2004. PMID: None.
12. O’Brien, S, Ferrajoli A. A patient with chronic lymphocytic leukemia treated with fludarabine/cyclophosphamide/rituximab. Case Studies In Lymphoma 2, 2003. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

1. Ferrajoli A. New therapeutic agents in CLL. None, 2006.
2. Ferrajoli A. Leukemias. The University of Texas, M.D. Anderson Cancer Center Color-Matrix Cancer Staging and Chemotherapy Handbook. None, 2005.
3. Ferrajoli A. The relevance of age and symptoms in CLL. None, 2004.
4. Ferrajoli A. Leukemias: The University of Texas, M.D. Anderson Cancer Center Color-Matrix Cancer Staging and Chemotherapy Handbook. None, 2003.

Other Articles

1. Braish, J, Cerchione, C, Ferrajoli, A An overview of prognostic markers in patients with CLL. Frontiers in Oncology 14, 2024. PMID: 38817892.
2. Nasnas P, Cerchione C, Musuraca G, Martinelli G, Ferrajoli A How I Manage Chronic Lymphocytic Leukemia. Hematol Rep 15(3):454-464, 2023. PMID: 37606492.
3. Gordon MJ, Ferrajoli A Unusual complications in the management of chronic lymphocytic leukemia. Am J Hematol 97 Suppl 2(S2):S26-S34, 2022. PMID: 35491515.
4. Rivera D, Ferrajoli A Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Curr Oncol Rep 24(8):1003-1014, 2022. PMID: 35366167.
5. Desikan SP, Venugopal S, Ferrajoli A BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?. Expert Rev Hematol 15(5):403-409, 2022. PMID: 35507054.
6. Vitale, C, Gibbons, JL, Ferrajoli, A Targeted Treatment of Chronic Lymphocytic Leukemia. OncoTargets and Therapy 14:5507-5519, 2021. PMID: 35002256.
7. Rivera D, Takahashi K, Durand JB, Ferrajoli A Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder. Mediterr J Hematol Infect Dis 13(1):e2021044, 2021. PMID: 34276913.
8. Strati P, Ferrajoli A Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. Drugs Aging 36(9):841-851, 2019. PMID: 31055788.
9. Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol 3(None):None, 2019. PMID: 32914014.
10. Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 18(8):508-518.e14, 2018. PMID: 29934061.
11. Autore F, Strati P, Laurenti L, Ferrajoli A Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica 103(6):931-938, 2018. PMID: 29748447.
12. Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. Am Soc Clin Oncol Educ Book 38(None):580-591, 2018. PMID: 30231393.
13. Boddu P, Ferrajoli A Prognostic Factors in the Era of Targeted Therapies in CLL. Curr Hematol Malig Rep 13(2):78-90, 2018. PMID: 29473123.
14. Khan M, Gibbons JL, Ferrajoli A Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia. Onco Targets Ther 10:1909-1914, 2017. PMID: 28408842.
15. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12(None):34-42, 2016. PMID: 27720213.
16. Falchi L, Baron JM, Orlikowski CA, Ferrajoli A BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia. Mediterr J Hematol Infect Dis 8(1):e2016011, 2016. PMID: 26977270.
17. Ferrajoli A, Faderl S, Keating MJ Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 6(9):1231-8, 2006. PMID: 17020457.
18. Ferrajoli A, Faderl S, Ravandi F, Estrov Z The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6(8):671-679, 2006. PMID: 17168672.
19. Han XY, Lin P, Amin HM, Ferrajoli A Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response. Am J Clin Pathol 123(4):612-617, 2005. PMID: 15743745.
20. Ferrajoli A, O'Brien S, Keating MJ Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther 1(6):1059-1065, 2001. PMID: 11728236.
21. Ferrajoli A, Fizzotti M, Liberati AM, Grignani F Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches. Crit Rev Oncol Hematol 22(3):151-174, 1996. PMID: 8793272.
22. Donti E, Ferrajoli A, Donti GV, Senatore M, Ardisia C, Saglio G, Liberati AM Effect of IFN alpha therapy on secondary Ph1-positive clones. Br J Haematol 81(3):451-453, 1992. PMID: 1390223.

Abstracts

1. Senapati J, Jabbour E, Short NJ, Tang G, Haddad FG, Jain N, Issa GC, Kadia TM, Daver N, Ferrajoli A, Kwari M, Garcia-Manero G, Montalban-Bravo G, Nasnas PE, Pemmaraju N, Garris R, Ravandi F, Kantarjian HM. Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy. ASH 2023, 2023. PMID: None.
2. Shaim H, Rafei H, Kaplan M, Basarn R, Daher M, Shanley M, Banerjee P, Kumar B, Nunez Cortes AK, Islam S, Jiang XR, Kerbauy LN, Lin P, Gokdemir E, Uprety N, Sunil Acharya S, Mendt MC, Garcia LM, Biederstädt A, Liu B, Liu E, Sonny Ang S, Burger JA, Wierda WG, Ferrajoli A, Shpall EJ MD, Rezvani K. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis. ASH 2023, 2023. PMID: None.
3. Senapati J, Kantarjian HM, Jabbour E, Babakhanlou R, Kadia TM, Borthakur G, Konopleva MY, Wierda WG, Burger JA, Issa GC, Maiti A, Balkin HS, Kelly M, Garris R, Ferrajoli A, Garcia-Manero G, Valero YA, Kebriaei P, Short NJ, Jain N, MD, Ravandi F. Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL). ASH 2023, 2023. PMID: None.
4. Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, Bertilaccio MT S, Calin GA, R-C CD, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, and Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. ASH 2023, 2023. PMID: None.
5. Ferrajoli A, Follows G, Marmor Y, Bourjlian SA, Jack Roos J, Bajwa N, Madhira V, Nozaki K, Palhares De Miranda PAP, and Krish Patel K. Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib. ASH 2023, 2023. PMID: None.
6. Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kaźmierczak M, Jurczak W, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy AL, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen AC, and Mazyar Shadman M. Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). ASH 2023, 2023. PMID: None.
7. Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Alvarado Valero Y, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA, MD, PhD, Jabbour E, Andreeff M, Ravandi F, Tidwell RS, Wang X, Konopleva MY, Garcia-Manero G, Kantarjian HM, Courtney D DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update. ASH 2023, 2023. PMID: None.
8. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Swaminathan M, Takahashi K, Estrov Z, Konopleva MY, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Valero YA, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, and Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. ASH 2023, 2023. PMID: None.
9. Bazinet A, Kantarjian HM, Borthakur G, Yilmaz M, Bose P, Jabbour E, Valero YA, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa GC, Jain N, Hammond DE, Bull-Linderman D, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Sasaki K, Garcia-Manero G, Ravandi F, and Kadia TM. Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. ASH 2023, 2023. PMID: None.
10. Follows G, Ferrajoli A, Byrd JC, Shaw B, Nozaki K, Stewart K Palhares De Miranda PAP, and Sharman JP. Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib. ASH 2023, 2023. PMID: None.
11. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker PA, Karlsson K, Ghia P, Janssens A, Cymbalista F, Byrd JC, Ferrant E, Ferrajoli A, William G Wierda WG, Munugalavadla V, Wachira CW, C-C W, and Woyach JA. Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN. ASH 2023, 2023. PMID: None.
12. Jain N, Thompson P, Jain A, Burger JA, Ferrajoli A, Senapati J, Takahashi K, Swaminathan M, Estrov Z, Borthakur G, Bose P, Kadia TM, Pemmaraju N, Sasaki K, Bansal D, Konopleva MY, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel KP, Wang W, Wang SA, Jorgensen JL, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating, MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/TP53 Mutation: Six-Year Follow-up Analyses. ASH 2023, 2023. PMID: None.
13. Nguyen D, Kantarjian HM, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasnas C, Nasr L, Garris R, Konopleva MY, Ravandi F, and Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. ASH 2023, 2023. PMID: None.
14. Jones J, George S B, Peterson B C, Ha T T, Burger JA, Nitin J, Keating MJ, Wierda G W, Durand J Ferrajoli A. Hypertension, Cardiovascular and Renal Complications Observed in Patients withChronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib. 62nd Annual ASH Meeting. Blood 136(1):27 - 28, 2020. PMID: None.
15. Jain N, Thompson P, Burger A J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Prithviraj B, kadia T, Pemmaraju N, Sasaki K, Gar N, Wang X, Kanga, - Shamanna R, Patel K, Jorgensen J, sa W, Plunkett W, Gandhi V, Kantarjian K, O, Brien S, Keating M, Wierda W. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First - line Treatment of patients with CLL with Mutated IGHV and without TP53 Aberrations. 2019 iwCLL Meeting. None, 2019. PMID: None.
16. Duque A, Randhawa J, Kantarjian H, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda W, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML. None 140(1):30-39, 2018. PMID: 30071517.
17. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D'Arena G, Murru R, Vincelli DI, Reda G, Vitale C, Ferrajoli A, Laurenti L. LDH Levels Predict Progression-Free Survival in Treatment-NaÏVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia. None, 2016. PMID: None.
18. Morabito F, D'Arena G, Murru R, Vincelli DI, Rede G, Vitale C, Ferrajoli A, Laurenti L. 58th Annual Meeting and Exposition (December 3-6, 2016). None, 2016. PMID: None.
19. Vitale C, Falchi L, Hacken ten E, Gao H, Shaim a H, Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda G W, Rezvani K, Reuben M J, Burger J, Keating J M, Ferrajoli A. Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide. Blood 126(23):1748, 2015. PMID: None.
20. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nuckel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. CD49D has independent negative predictive power for overall survival in chronic lymphocytic leukemia: results from multi-center pooled analysis. Haematologica 32(9):897-904, 2014. PMID: 24516016.
21. Strati P, Wierda WG, Burger JA, Ferrajoli A, Lerner S, Keating MJ, O'Brien SM. Prolonged cytopenia related to fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukemia. Cancer 119(21):3805-3811, 2013. PMID: 23943357.
22. Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012. PMID: None.
23. Falchi L, Trinh LX, Marom EM, Truong M, Schlette E, Sargent RL, Wang X, Smith SC, Lerner S, Keating MJ, Ferrajoli A. Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes. Blood 120(21), 2012. PMID: None.
24. Rodriguez MA, Cheng L, DeJesus AY, Ferrajoli A, Burke TW. Chemotherapy Use within the Last 14 Days of Life in Patients with Hematological Malignancies. Blood 120(21), 2012. PMID: None.
25. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien SM, Kornblau SM, Kantarjian HM, B-N L, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood 120(21), 2012. PMID: None.
26. Wierda WG, Balakrishnan K, Ferrajoli A, O'Brien S, Burger JA, Kadia TM, Cortes JE, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi VV. Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with In Vivo Mechanism of Action for Combination Chemotherapy. Blood 120(21), 2012. PMID: None.
27. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour EJ, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Ferrajoli A, Kadia TM, O'Brien S, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). Blood 120(21), 2012. PMID: None.
28. Strati P, Abruzzo LV, Wierda W, Lerner S, O'Brien SM, Kantarjian HM, Ferrajoli A, Keating MJ. Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12. Blood 120(21), 2012. PMID: None.
29. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, Lerner S, Zacharian G, Huang X, James DF, Buggy JJ, Kantarjian HM, O'Brien SM. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chrinic Lymphocytic Leukemia (CLL) Patients. Blood 120(21), 2012. PMID: None.
30. Poon LM, Fox PS, Samuels BI, O'Brien SM, Ferrajoli A, Keating MJ, Jabbour EJ, Hsu Y, Abruzzo LV, Champlin RE, Bassett R, Khouri IF. Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Wh Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience. Blood 120(21), 2012. PMID: None.
31. Falchi L, Keating MJ, Lerner S, Wang X, Strom SS, Wierda WG, Ferrajoli A. Other Cancers in Patients with Chronic Lymphocytic Leukemia Requiring Therapy: Association with Prognostic Factors and Impact on Survival. Blood 120(21), 2012. PMID: None.
32. Rozovski U, Calin G, Tetsirp S, D'Abundo L, Harris D, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien SM, Wiereda WG, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic lymphocytic Leukemia (CLL). Blood 120(21), 2012. PMID: None.
33. Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien SM, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood 120(21), 2012. PMID: None.
34. Takahashi K, Kantarjian HM, Abruzzo LV, Borthakur G, Garcia-Manero G, O'Brien SM, Faderl S, Luthra R, Wierda WG, Ferrajoli A, Pierce SA, Ravandi F, Cortes JE. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. Blood 120(21), 2012. PMID: None.
35. Romo CG, Kantarjian HM, O'Brien S, Quintas-Cardama A, Kornblau SM, Faderl S, Ferrajoli A, Wierda WG, Pierce SA, Jabbour EJ, Cortes JE. Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome. Blood 120(21), 2012. PMID: None.
36. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, Andreeff M, Garris R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood 120(21), 2012. PMID: None.
37. Ferrajoli A, Falchi L, O'Brien S, Wierda W, Faderl S, Smith SC, Ayala AB, Kantarjian HM, Keating MJ. Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Blood 120(21), 2012. PMID: None.
38. Katragadda L, Kantarjian HM, Garcia-Manero G, Kadia TM, Ferrajoli A, Jabbour EJ, Quintas-Cardama A, Konopleva M, Maniar M, Wilhelm F, Ravandi F, Cortes JE. Phase 1/2 Single Arm Study of Rigosertib (ON01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. Blood 120(21), 2012. PMID: None.
39. Jain P, Trinh LX, Benjamini O, Lerner S, Wang X, Ferrajoli A, Burger JA, Estrov Z, Wierda WG, Kantarjian HM, O'Brien S, Abruzzo LV, Keating MJ. Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) at Presentation - Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q cytogenetic Abnormality. Blood 120(21), 2012. PMID: None.
40. Lee HJ, Wierda WG, Ferrajoli A, Burger JA, Trinh L, Lerner S, Keating MJ, O'Brien SM. Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia. J Clin Oncol 30, 2012. PMID: None.
41. Wierda WG, O'Brien SM, Faderl S, Ferrajoli A, Burger JA, Estrov Z, Tambaro FP, Kadia TM, Lerner S, Kantarjian H, Keating MJ. Pretreatment prognostic factors associated with outcomes for first-line FCR-based treatments in previously untreated CLL. J Clin Oncol 30, 2012. PMID: None.
42. Ohanian M, Kantarjian H, Quintas-Cardama A, O'Brien SM, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton EM, Trinh L, Ferrajoli A, Jabbour E, Kadia TM, Cortes JE. Clinical impact of dose intensity of initial tyrosine kinase inhibitor (TKI) therapy in accelerated-phase CML (CML-AP). J Clin Oncol 30, 2012. PMID: None.
43. Falchi L, Keating MJ, Badoux XC, Wierda WG, O'Brien SM, Smith SC, Wen S, Kantarjian H, Ferrajoli A. Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). J Clin Oncol 30, 2012. PMID: None.
44. Strati P, Keating MK, Wierda WG, Badoux X, Calin S, Reuben J, O'Brien SM, Kornblau S, Kantarjian H, Lee BN, Ferrajoli A. Long-lasting responses to Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 120(21):3932, 2012. PMID: None.
45. Ravandi F, Thomas DA, O'Brien S, Garris R, Faderl S, Shan J, Borthakur G, Burger JA, Ferrajoli A, Kebriaei P, Champlin R, Estrov Z, Wang Sa A, Jorgensen JL, Luthra R, Cortes JE, Kantarjian HM. Detection of minimal residual leukemia predicts the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors plus chemotherapy. Blood 118, 2011. PMID: None.
46. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and rituximab for de novo Burkitt lymphoma/leukemia. Blood 118, 2011. PMID: None.
47. Hsu Y, Saliba RM, Okoroji GJ, O'Brien S, Ferrajoli A, Abruzzo LV, Champlin R, Keating MJ, Khouri IF. Feasibility analysis of nonmyeloablative allogeneic stem cell transplantation (NST) in patients with chronic lymphocytic leukemia (CLL) and 17p- deletion. Blood 118, 2011. PMID: None.
48. Liu-Dumlao T, O'Brien S, Cortes JE, Thomas DA, Faderl S, Jabbour E, Koller C, Garris R, Kebriaei P, Champlin R, Borthakur G, Ferrajoli A, Kantarjian HM, Ravandi F. Combination of the hypercvad regimen with dasatinib in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) or lymphoid blast phase of chronic myeloid leukemia (CML-LB). Blood 118, 2011. PMID: None.
49. Nazha A, Cortes JE, Faderl S, Pierce S, Garcia-Manero G, O'Brien S, Ferrajoli A, Kadia T, Borthakur G, Luthra R, Kantarjian HM, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 (FLT3) at complete response and relapse in patients with acute myeloid leukemia. Blood 118, 2011. PMID: None.
50. Lee HJ, Kantarjian HM, Thomas DA, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda WG, Burger JA, Cortes JE, O'Brien S, Ravandi F. Long-term follow-up of combined hypercvad (hCVAD) regimen with dasatinib (Db) in the front line therapy of patients (pts) with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Blood 118, 2011. PMID: None.
51. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment patient characteristics associated with achieving bone marrow minimal residual disease-free status with frontline fludarabine, cyclophosphamide, rituximab (FCR) chemoimmunotherapy for CLL. Blood 118, 2011. PMID: None.
52. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for adult lymphoblastic leukemia (ALL) are mainly influenced by age and status of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) after therapy with the modified hyper-CVAD (with or without rituximab) regimen. Blood 118, 2011. PMID: None.
53. Liu-Dumlao T, Kantarjian HM, Quintas-Cardama A, Jabbour E, Burger JA, Alvarado Y, Burton EM, Trinh LX, Ravandi F, Ferrajoli A, O'Brien S, Cortes JE. Clinical significance of myelosuppression associated with the use of dasatinib and nilotinib as initial therapy in chronic phase (CP) of chronic myeloid leukemia (CML). Blood 118, 2011. PMID: None.
54. Li P, Liu Z, Harris D, Ferrajoli A, Wang Y, Hazan-Halevy I, Grgurevic S, Wierda WG, Burger JA, O'Brien S, Faderl S, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 induces granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor-a expression in chronic lymphocytic leukemia (CLL) cells. Blood 118, 2011. PMID: None.
55. Nazha A, Ravandi F, Kantarjian HM, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia (AML). Blood 118, 2011. PMID: None.
56. Pozadzides JV, Keating M, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang SA, Lerner S, Ferrajoli A. Initial experience with lenalidomide as consolidation treatment in patients with chronic lymphocytic leukemia and residual disease after chemotherapy. Blood 118, 2011. PMID: None.
57. Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A. Final Analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 118, 2011. PMID: None.
58. Ohanian M, Kantarjian HM, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton EM, Trinh LX, Ferrajoli A, Jabbour E, Kadia T, Cortes JE. Frontline tyrosine kinase inhibitors (TKI) as initial therapy for patients with chronic myeloid leukemia in accelerated phase (CML-AP). Blood 118, 2011. PMID: None.
59. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A phase I/II trial of fludarabine, bendamustine, and rituximab (FBR) chemoimmunotherapy for previously treated patients with CLL. Blood 118, 2011. PMID: None.
60. Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L, Calin S, Kantarjian HM, Keating MJ. Combination therapy with ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): Results of a phase II trial. Blood 118, 2011. PMID: None.
61. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute leukemia and myelodysplastic syndrome: Outcomes in patients with chronic lymphocytic leukemia (CLL) at MD Anderson Cancer Center (MDACC). Blood 118, 2011. PMID: None.
62. Badoux X, O'Brien S, Wierda WG, Faderl S, Estrov Z, Yerrow K, Kantarjian HM, Keating MJ, Ferrajoli A. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a phase II trial. Blood 116(21):1023-1024, 2010. PMID: None.
63. Ravandi F, Estey EH, Cortes JE, O'Brien S, Pierce SA, Brandt M, Ferrajoli A, Borthakur G, Konopleva M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamIcin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL). Blood 116(21):472, 2010. PMID: None.
64. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera J, Hagemeister F, Kantarjian H. Long-term outcome for de novo or minimally treated Burkitt-type lymphoma/leukemia (BL/B-ALL) after therapy with hyper CVAD and rituximab. Blood 116(21):743, 2010. PMID: None.
65. Eghtedar A, Verstovsek S, Cortes JE, Estrov Z, Burger JA, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Newton R, Kantarjian H, Ravandi F. Phase II study of the JAK2 inhibitor, INCB018424, in patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML). Blood 116(21):225, 2010. PMID: None.
66. Li L, Kantarjian H, Zhao M, O'Brien S, Jabbour E, Quintas-Cardama A, Burton E, Faderl S, Ferrajoli A, Cortes JE. Outcome of patients (pts) with chronic myeloid leukemia (CML) after failure to 2nd and 3rd tyrosine kinase inhibitors (TKIs). Blood 116(21):529-530, 2010. PMID: None.
67. Naqvi K, Ravandi F, Kantarjian H, Borthakur G, Ferrajoli A, Thomas DA, Koller CA, Konopleva M, Byrd A, Kwari M, Faderl S. Phase II study of the combination of clofarabine plus idarubicin and cytarabine (CIA) in patients with relapsed/refractory acute myeloid leukemia (AML). Blood 116(21):464-465, 2010. PMID: None.
68. Eghtedar A, Faderl S, Kantarjian H, O'Brien S, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce SA, Shan J, Cortes JE, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid (ATRA) with chemotherapy or with arsenic trioxide (ATO). Blood 116(21):474, 2010. PMID: None.
69. Pemmaraju N, Kantarjian H, Garcia-Manero G, Faderl S, Ferrajoli A, Borthakur G, Kadia T, Cortes JE. Phase I study results of gimatecan in the treatment of myelodysplastic syndrome (MDS). Blood 116(21):785, 2010. PMID: None.
70. Ravandi F, Jorgensen J, O'Brien S, Thomas DA, Faderl S, York S, Burger JA, Ferrajoli A, Pierce S, Keating M, Kantarjian H. Phase II study of sequential therapy with cladribine followed by an extended course of rituximab in patients with hairy cell leukemia. Blood 116(21):1020-1021, 2010. PMID: None.
71. Ferrajoli A, Badoux X, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Kantarjian H, Keating MJ. The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 116(21):600, 2010. PMID: None.
72. Wendtner C, Hillman P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, de Parseval LM, Chanan-Khan AA. Final results of the phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 study). Blood 116(21):592, 2010. PMID: None.
73. Jabbour E, Kantarjian H, Cornelison AM, Kadia T, M-A W, Abruzzo LV, Burger JA, Ferrajoli A, Garcia-Manero G, Cortes JE. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during second generation tyrosine kinase inhibitors (2nd TKI) therapy in patients (pts) with chronic myeloid leukemia. Blood 116(21):527, 2010. PMID: None.
74. Khouri I, Bassett R, Cano P, O'Brien S, Hsu Y, Bueso-Ramos CE, Harrell R, G-J O, de Padua Silva L, Ferrajoli A, Champlin R, McMannis J, Fernandez-Vina M. Human-leukocyte-histocompatibility antigens predict response to rituximab and donor lymphocyte infusion (DLI) after non-myeloablative allogeneic stem transplantation (NST) for chronic lymphocytic leukemia (CLL). Blood 116(21):1055, 2010. PMID: None.
75. Liu Z, Hazan-Halevy I, Harris D, Li P, Ferrajoli A, Faderl S, Keating M, Estrov Z. Signal transducer and activator of transcription (STAT)-3 activates nuclear factor (NF)-kB in chronic lymphocytic leukemia (CLL) cells. Blood 116(21):170, 2010. PMID: None.
76. Badoux X, Wierda WG, O'Brien SM, Faderl S, Estrov E, Yerrow KA, Keating MJ, Ferrajoli A. A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. J Clin Oncol 28(15(S)):489, 2010. PMID: None.
77. Parikh S, Wierda WG, Badoux X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Lerner S, Kantarjian H, Keating MJ. Comparison of fludarabine (F) plus cyclophosphamide (C) veruss FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). J Clin Oncol 28(15(S)):491, 2010. PMID: None.
78. Faderl S, Ravandi F, Garcia-Manero G, Huang X, Jabbour E, Kadia T, Ferrajoli A, Estrov Z, Feliu J, Schroeder H, Kwari M, Kantarjian H. Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): Clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood 116(21):152, 2010. PMID: None.
79. Batty N, Badoux XC, Keating M, Lin E, Lerner S, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda WG. Pretreatment factors associated with second malignancies occuring after frontline fludarabine, cyclophosphamide, and rituximab (FCR) in patients with chronic lymphocytic leukemia (CLL). Blood 114(22):1339-1340, 2009. PMID: None.
80. Santos FPS, O'Brien S, Thomas DA, Cortes J, Faderl S, Jorgensen JL, Garris R, Koller C, Kebriaei P, Ferrajoli A, Kantarjian H, Ravandi F. Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). Blood 114(22):984-985, 2009. PMID: None.
81. Ravandi F, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Jones D, Jabbour E, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Ferrajoli A, O'Brien S. Combination of the hypercvad regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 114(22):806-807, 2009. PMID: None.
82. Ayoubi M, Kantarjian HM, Wierda W, Ferrajoli A, Hiteshew J, Estrov Z, Cortes-Franco J. A phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. Blood 114(22):862-863, 2009. PMID: None.
83. Badoux XC, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating M, Estrov Z. Cross-talk between CLL cells and endothelial cells in the bone marrow microenvironment: Role of signal transducer and activator of transcription (stat)-3. Blood 114(22):511, 2009. PMID: None.
84. Rytting M, Thomas DA, Franklin AR, Jabbour E, Wierda W, Faderl S, Ferrajoli A, Cortes J, O'Brien S, Kantarjian H. Pediatric-based therapy for young adults with newly diagnosed lymphoblastic leukemia. Blood 114(22):804, 2009. PMID: None.
85. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, de Lima M, Pierce S, Brandt M, Borthakur G, Ferrajoli A, Wierda WG, Koller CA, Kantarjian HM. Characteristics and outcome of patients with acute myeloid leukemia (AML) refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 114(22):430, 2009. PMID: None.
86. Khouri IF, Bassett RL, Jr, Cano P, O'Brien S, Hsu Y, Bueso-Ramos CE, Harrell R, G-J O, De Padua Silva L, Ferrajoli A, Wierda W, Kantarjian H, Champlin R, McMannis J, Fernandez-Vina, M. Human-leukocyte-histocompatibility antigens (HLA-A1+, A2-, B44-) and serum immunoglobulin (Ig)G with CD4 levels predict response to graft-versus-leukemia (GVL) and overall survival, respectively, after non-myeloablative allogeneic stem transplantation (NST) for chronic lymphocytic leukemia (CLL). Blood 114(22):902-903, 2009. PMID: None.
87. Verma D, Balakrishnan K, O'Brien S, Thomas DA, Ferrajoli A, Wierda WG, Verma A, Faderl S, Bickel SM, Bantia S, Kantarjian HM, Keating MJ, Ghandi V, Ravandi F. Phase II, single center study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia (CLL). Blood 114(22):935-936, 2009. PMID: None.
88. Cortes J, O'Brien S, Jones D, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Efficacy of nilotinib in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 114(22):144-145, 2009. PMID: None.
89. Ferrajoli A, Badoux XC, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, B-N L, Reuben JM, Kantarjian H, Keating M. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 114(22):89-90, 2009. PMID: None.
90. Parikh SA, Keating M, O'Brien S, Ferrajoli A, Faderl S, Koller C Estrov Z, Lerner S, Wierda WG. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood 114(22):91-92, 2009. PMID: None.
91. Parikh SA, Kantarjian H, Garcia-Manero G, Jabbour E, Kadia T, Ravandi F, Ferrajoli A, Estrov Z, Feliu J, Faderl S. Clofarabine plus low-dose cytarabine induction followed by consolidation with clofarabine plus low-dose cytarabine alternating with decitabine as frontline therapy for patients (pts) with acute myeloid leukemia (AML) >60 years (yrs). Blood 114(22):813, 2009. PMID: None.
92. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garris R, Keating MJ, O'Brien S. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome for patients with de novo Philadelphia negative precursor B-cell acute lymphoblastic leukemia (ALL). Blood 114(22):344-345, 2009. PMID: None.
93. Wang XS, Mendoza TR, Broadway JB, Mobley GM, Keating M, Cleeland CS, Ferrajoli A. Symptom profiles in patients with chronic lymphocytic leukemia: Validation and application of the M. D. Anderson Symptom Inventory. Blood 114(22):567, 2009. PMID: None.
94. Parikh SA, Kantarjian H, Ravandi F, Borthakur G, Faderl S, Verma A, Ferrajoli A, Estrov Z, Pierce S, Cortes J. Incidence, clinical features and outcome of patients with differentiation syndrome in acute promyelocytic leukemia treated with all-trans retinoic acid (ATRA) alone versus ATRA plus idarubicin versus ATRA plus arsenic trioxide. Blood 114(22):432, 2009. PMID: None.
95. Badoux XC, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda WG. Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL). Blood 114(22):3431-3432, 2009. PMID: None.
96. Badoux XC, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo LV, Wierda WG. Patients with relapsed CLL and 17p deletion by FISH have very poor survival outcomes. Blood 114(22):513-514, 2009. PMID: None.
97. Quintas-Cardama A, Kantarjian HM, O'Brien S, Ravandi F, Ferrajoli A, Garcia-Manero G, Cortes J. Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. Blood 112(11):735, 2008. PMID: None.
98. Ferrajoli A, Faderl S, O'Brien S, Wierda W, Ayala A, Smith S, Brown TC, Kantarjian H, Keating M. Experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 112(11):1088, 2008. PMID: None.
99. Ferrajoli A, O'Brien S, Wierda W, Faderl S, Kornblau S, Yerrow K, Estrov Z, Kantarjian H, Keating M. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 112(11):23, 2008. PMID: None.
100. Glezer E, Ferrajoli A, Reuben JM, Corral LG. Treatment with lenalidomide (Revlimid) upregulates CD40 expression on CLL cells and increases their sensitivity to CD40-mediated cytotoxicity in vitro. Blood 112(11):1087, 2008. PMID: None.
101. Henderson JD, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, Wierda WG. Integrating newer prognostic factors in evaluation of previously treated patients with CLL receiving salvage treatment. Blood 112(11):723-724, 2008. PMID: None.
102. Hazan-Halevy I, Harris D, Liu Z, Ferrajoli A, Keating MJ, Estrov E. STAT3 is constitutively phosphorylated on serine 727 residues, activates transcription, and plays a major role in the pathogenesis of B-cell chronic lymphocytic leukemia. Blood 112(11):387-388, 2008. PMID: None.
103. Borthakur G, Kantarjian HM, O'Brien SM, Jones D, Koller C, Nicaise C, Garcia-Manero G, Ferrajoli A, Cortes JE. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). J Clin Oncol 26(15(S)):375s, 2008. PMID: None.
104. Ravandi F, Faderl S, Thomas DA, Brown D, Garris R, Borthakur G, Ferrajoli A, Cortes JE, Kantarjian HM, O'Brien SM. Phase II study of combination of the hyper-CVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). J Clin Oncol 26(15(S)):377s, 2008. PMID: None.
105. Schlette E, Tam CS, Herling M, Bueso-Ramos C, Wierda W, Ferrajoli A, O'Brien S, Keating M, Jones D. High T-cell lymphoma breakpoint 1 (TCL1) levels are associated with lack of response and inferior outcome following fludarabine, cyclophosphamide, rituximab (FCR) frontline therapy in patients with chronic lymphocytic leukemia (CLL). Blood 112(11):726, 2008. PMID: None.
106. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen JK, Konopleva M, Burger J, Ferrajoli A, George S, Kantarjian H. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 112(11):1026, 2008. PMID: None.
107. Gao H, Ferrajoli A, Cohen EN, B-N L, Tin S, O'Brien S, Wierda WG, Estrov Z, Faderl S, Keating MJ, Reuben JM. Treatment with lenalidomide has a positive immunomodulatory effect in patients with chronic lymphocytic leukemia. Blood 112(11):733-734, 2008. PMID: None.
108. Faderl S, Borthakur G, Ravandi F, Huang X, Beran M, Ferrajoli A, Koller CA, Thomas DA, Verstovsek S, Kwari M, Kantarjian H. Results of a randomized phase 2 study of clofarabine plus cytarabine (CA) vs clofarabine plus idarubicin (CI) vs clofarabine, idarubicin, plus cytarabine (CIA) as salvage therapy in acute myeloid leukemia (AML). Blood 112(11):354-355, 2008. PMID: None.
109. Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G, Garcia-Manero G, Letvak LA, Kantarjian H. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 112(11):170, 2008. PMID: None.
110. Tam CS, Wierda W, O'Brien SM, Lerner S, Abruzzo LV, Ferrajoli A, Kantarjian HM, Keating MJ. The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients. J Clin Oncol 26(15(S)):380s, 2008. PMID: None.
111. Thomas DA, Kantarjian H, Faderl S, Wierda WG, Ferrajoli A, Burger JA, Cortes J, Konopleva M, Ravandi F, Garcia-Manero G, O'Brien S. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). Blood 112(11):674, 2008. PMID: None.
112. McClain WD, Gunn SR, Bolla AR, Barron LL, Gorre ME, Bahler DW, Mellink CHM, van Oers MHJ, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11. Blood 112(11):384-385, 2008. PMID: None.
113. Cortes JE, O'Brien SM, Ferrajoli A, Borthakur G, Burger J, wierda W, Garcia-Manero G, Letvak L, Kantarjian HM. Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). J Clin Oncol 26(15(S)):376s, 2008. PMID: None.
114. Hazan-Halevy I, Harris D, Liu Z, Ferrajoli A, Keating MJ, Estrov E. Importin-Beta 1 and nucleus transporter chromosome region maintenance 1 (CRM1) constitute the nucleocytoplasmic transport system of STAT3 in blood-derived CLL cells. Blood 112(11):388, 2008. PMID: None.
115. Cortes J, O'Brien S, Borthakur G, Jones D, Ravandi F, Koller C, Mesina O, Ferrajoli A, Shan J, Kantarjian H. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 112(11):74, 2008. PMID: None.
116. Wierda WG, O'Brien SM, Faderl SH, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian HM, Keating MJ. CFAR, an active frontline regimen for high-risk patients with CLL, including those with del 17p. Blood 112(11):729, 2008. PMID: None.
117. Ferrajoli A, Keating MJ, Wierda WG, O'Brien SM, Padmanabhan S, Czuczman MS, Chanan-Khan, AA. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. Blood 110(11):232a, 2007. PMID: None.
118. Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger J, Schlette E, Abruzzo L, Lerner S, Keating M. Complex karyotypic abnormalities detected by conventional cytogenetic analysis more strongly predict survival than FISH, ZAP70, or IgVH mutation status for previously treated patients with CLL. Blood 110(11):615a, 2007. PMID: None.
119. Cortes J, O'Brien S, Jones D, Koller C, Borthakur G, Nicaise C, Henerson L, Ferrajoli A, Kantarjian H. Efficacy of Dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 110(11):17a, 2007. PMID: None.
120. Faderl S, Bornmann W, Maxwell D, Peng Z, Van Q, Liu Z, Verstovsek S, Ferrajoli A, Kantarjian HM, Estrov Z. Molecular targeting in acute myeloid leukemia (AML) therapy: APcK110 is a new inhibitor of c-lot activity in AML blasts. J Clin Oncol 25(18S), 2007. PMID: None.
121. Ferrajoli A, O'Brien SM, Faderl SH, Wierda WG, Jorgensen JL, Keating MJ. The combination of rituximab and GM-CSF as frontline treatment for elderly patients with chronic lymphocytic leukemia. Leuk & Lymph 48 (Suppl 1):161, 2007. PMID: None.
122. Jabbour E, Kantarjian H, Jones D, Verstovsek S, Ferrajoli A, Ravandi F, O'Brien S, Cortes J. Characteristics and outcome of patients with chronic myeloid leukemia (CML) and T3151 mutation following failure of Imatinib Mesylate therapy. Blood 110(11):577-578a, 2007. PMID: None.
123. Hazan-Halevy I, Ferrajoli A, Harris D, Mandal PK, McMurray JS, Keating M, Estrov Z. Constitutive serine phosphorylation of STAT3 induces proliferation of chronic lymphocytic leukemia cells. Cytokine 39(1):15, 2007. PMID: None.
124. Ravandi F, J-P I, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O'Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized study of Decitabine versus observation or continued cytotoxic chemotherapy in patients with intermediate and poor risk acute myeloid leukemia in first or subsequent complete remission. Blood 110(11):841a, 2007. PMID: None.
125. Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas DA, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Results of an exploratory study of oral (po) and intravenous (iv) Clofarabine in patients with myelodysplastic syndrome. Blood 110(11):436a, 2007. PMID: None.
126. Cortes J, O'Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 110(11):17a, 2007. PMID: None.
127. Faderl SH, Van Q, Koch PE, Harris DM, Halevi I, Liu Z, Wang Y. Janus kinase (JAK)-2 does not play a role in Bcr-Abl signaling in Philadelphia chromosome (Ph)-positive (p190) acute lymphoblastic leukemia (ALL) cells. Blood 110(11):127-128b, 2007. PMID: None.
128. Tam CS, Keating MJ, O'Brien S, Ferrajoli A, Abruzzo LV, Lerner S, Faderl S, Kantarjian H, Wierda W. The natural history and treatment outcome of de-novo chromosome 17p deletion CLL: A single institution experience with 48 patients. Blood 110(11):608a, 2007. PMID: None.
129. Wierda WG, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Garcia-Manero G, Verstovsek S, Browning M, Lerner S, Keating M. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood 110(11):194a, 2007. PMID: None.
130. Ferrajoli A, Wang Y, O'Brien SM, Faderl SH, Harris DM, Van Q, Halevi I, Liu Z, Koch PE, Sensintaffar J, Burrows F, Kantarjian HM, Keating MJ, Estrov Z. The synthetic heat shock protein (Hsp) 90 inhibitor EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome positive (Ph)-positive acute lymphoblastic leukemia (ALL) cells. Blood 110(11):819a, 2007. PMID: None.
131. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). J Clin Oncol 25(18S), 2007. PMID: None.
132. Ferrajoli A, O'Brien SM, Faderl SH, Wierda WG, Reuben JM, Schlette EJ, Keating MJ. Therapy with lenalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk & Lymph 48 (Suppl 1):160, 2007. PMID: None.
133. Chanan-Khan AA, Czuczman MS, Padmanabhan S, Keating MJ, O'Brien SM, Wierda WG, Ferrajoli A. Clinical efficacy of lenalidomide in Fludarabine-refractory chronic lymphocytic leukemia patients. Blood 110(11):914a, 2007. PMID: None.
134. Safdar A, Rodriguez GH, Rueda-Jaimes AM, Wierda WG, Ferrajoli A, O'Brien S, Koller CA, Musher DM, Bodey GP, Keating MJ. Immunogenicity and safety of multi-dose granulocyte macrophage-colony stimulating factor (GM-CSF) immune enhancement in patients with chronic lymphocytic leukemia (CLL) receiving 23-valent polysaccharide pneumococcal vaccine (PPV23): A prospective, randomized, controlled trial. Proc. ICAAC, 2007. PMID: None.
135. Kadia TM, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstovsek S, Newsome W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A phase I study of the combination of the histone deacetylase inhibitor Vorinostat with Idarubicin in advanced acute leukemia. Blood 110(11):545a, 2007. PMID: None.
136. Hazan-Halevy I, Ferrajoli A, Harris D, Mandal PK, McMurray JS, Keating M, Estrov Z. Constitutively serine phosphorylated STAT3 provides chronic lymphocytic leukemia (CLL) cells with survival advantage and promotes their proliferation. Blood 110(11):344a, 2007. PMID: None.
137. Thomas DA, Kantarjian HM, Ravandi F, Faderl S, Garcia-Manero G, Wierda W, Ferrajoli A, Verstovsek S, Jones D, Letvak L, Champlin R, Cortes J, O'Brien S. Long-term follow-up after frontline therapy with the Hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 110(11):10a, 2007. PMID: None.
138. Faderl S, Wierda W, Ferrajoli A, O'Brien S, Ravandi F, Kantarjian HM, Showalter BL, Lerner S, Keating MJ. Update of experience with Fludarabine, Cyclophosphamide, Mitoxantrone plus Rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 110(11):193-194a, 2007. PMID: None.
139. Tam CS, Kantarjian HM, Shan J, Wierda WG, Ferrajoli A, Koller CA, Cortes J. Sokal and Hasford scores are able to predict cytogenetic response and survival in CML patients who failed prior therapy and are receiving salvage therapy with imatinib or other tyrosine kinase inhibitors. Blood 108(11):2157a, 2006. PMID: None.
140. Giles FJ, Carrol M, List A, Ferrajoli A, Thomas D, Cortes J, Feldman E, Roboz G. PTK787/ZK, an oral tyrosine kinase inhibitor, has activity in patients with agnogenic myeloid metaplasia (AMM). Blood 108(11):4920b, 2006. PMID: None.
141. Faderl S, Bornmann W, Maxwell D, Pal A, Z-H P, Shavrin A, Harris D, Van Q, Zhiming L, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM Estrov Z. APCK110, a novel and potent inhibitor of c-kit, blocks phosphorylation of AKT and STAT3, induces apoptosis, and inhibits proliferation of acute myeloid leukemia (AML) cells. Blood 108(11), 2006. PMID: None.
142. Ferrajoli A, O'Brien SM, Faderl SH, Wierda WG, Davis D, B-N L, Reuben JM, Schlette EJ, Kantarjian HM, Keating MJ. Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL). Blood 108(11):305a, 2006. PMID: None.
143. Ferrajoli A, O'Brien S, Faderl S, Weirda WB, Schlette E, Jorgensen JL, Reuben JM, Albitar M, Keating MJ. The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia. J Clin Oncol 24(18S):6602, 2006. PMID: None.
144. Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, Verstovsek S. PEG-Intron therapy in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPD): Final result of a Phase II study. Blood 108(11):3636a, 2006. PMID: None.
145. Thomas DA, Kantarjian HM, Heffner L, Stock W, Garcia-Manero G, Faderl S, Ferrajoli A, Giles F, Wierda W, Ravandi-Kashani F, Choy G, Berk GI, O'Brien S. Phase I trial of sphingosomal vincristine (SV, Marquibo(R) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL). Blood 108(11):4539b, 2006. PMID: None.
146. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller CA, Beran M, Kornblau SM, Andreeff M, Jones D, O'Brien S. Outcome after detection of minimal residual disease during treatment with modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Blood 108(11):1861a, 2006. PMID: None.
147. Faderl S, Ferrajoli A, Wierda WG, O'Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning ML, Keating MJ. The combination of alemtuzumab [continuous intravenous infusion (civ) followed by subcutaneous injection (sc)] plus rituximab has activity in patients (pts) with relapsed chronic lymphocytic leukemia (CLL). Blood 108(11):2827a, 2006. PMID: None.
148. Zhang Z, O'Brien S, Keating M, Jilani I, Kantarjian H, Estrov Z, Ferrajoli A, Giles F, Albitar M. Epidermal growth factor is an independent prognostic factor in patients with chronic lymphocytic leukemia. Blood 108(11):4952b, 2006. PMID: None.
149. Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Ravandi-Kashani F, Cortes J, Giles F, Andreeff M, Koller CA, Lerner S, Kantarjian HM, Keating MJ. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108(11), 2006. PMID: None.
150. Faderl S, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Wierda WG, Borthakur G, Thomas D, Cortes J, Kornblau SM, Estrov Z, Andreeff M, Beran M, Cortes J, Kornblau SM, Giles F, Huang X, Kwari M, Kantarjian HM. Clofarabine plus anthracycline combinations in acute myeloid leukemia (AML) salvage. Blood 108(11):159a, 2006. PMID: None.
151. Ferrajoli A. Interleukin-1 receptor antagonist and Interleukin-1 beta: Different roles in patients with chronic lymphocytic leukemia. Blood 108(11):4948b, 2006. PMID: None.
152. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Estey E, Ferrajoli A, Keating M, Giles F, Albitar M. Measurement and clinical relevance of proteasome enzymatic activity in plasma of patients with acute lymphoblastic leukemia. Blood 108(11):4475b, 2006. PMID: None.
153. Quintas-Cardama A, Kantarjian HM, Wierda W, Ferrajoli A, Chen R, Ravandi F, Plunkett W, Cortes J. A Phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML). Blood 108(11):2174a, 2006. PMID: None.
154. Faderl S, Wierda WG, O'Brien S, Ferrajoli A, Ravandi-Kashani F, Detry M, Kantarjian HM, O'Neal B, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: Results of a phase 2 study. Blood 108(11):2836a, 2006. PMID: None.
155. Giles FJ, Ravandi F, Cortes J, Estrov Z, Faderl S, Ferrajoli A, Garcia-Manero G, Thomas D, Wierda W, Verstovsek S. Phase I study of XL-119, a rebeccamycin analog, in patients with refractory hematological malignancies. Blood 108(11):1969a, 2006. PMID: None.
156. Thomas DA, Kantarjian HMN, Cortes J, Faderl S, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Andreeff M, Letvak LA, Jones D, Champlin R, O'Brien S. Outcome with Hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph)-positive acute lymphocytic leukemia (ALL). Blood 108(11):284a, 2006. PMID: None.
157. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Detry M, Ravandi F, Kantarjian HM, O'Neal B, Keating MJ. A phase II study of dluradabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R)(FCM-R) in previously untreated patients (pts) with CLL <70 years (yrs). J Clin Oncol 24(18S):6607, 2006. PMID: None.
158. Jabbour E, Kantarjian HM, Cortes J, Wierda WG, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovseek S, Garcia-Manero G, Davisson J, Giles F, Shan J, J-P I. Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with higher risk myelodysplastic syndrome (MDS). Blood 108(11):2652a, 2006. PMID: None.
159. Ravandi-Kashani F, Estrov Z, Ferrajoli A, Borthakur G, Beran M, Pierce S, Koller CA, Cortes J, Faderl S, Kantarjian HM. Phase II study of thymoglobulin, cyclosporine, and G-CSF for the initial treatment of aplastic anemia and low risk myelodysplastic syndrome. Blood 108(11):4830b, 2006. PMID: None.
160. Ma W, O'Brien S, Jilani I, Zhang X, Kantarjian H, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Variations in proteasome enzymatic activities in plasma of patients with acute myeloid leukemia and myelodysplastic syndrome and their value in predicting clinical behavior. Blood 108(11):4497b, 2006. PMID: None.
161. Hodge M, O'Brien S, Abdool A, Keating M, Jilani I, Kantarjian H, Ferrajoli A, Estrov Z, Giles F, Albitar M. Clinical significance of free circulating CD3 and CD5 in patients with chronic lymphocytic leukemia. Blood 108(11):4947b, 2006. PMID: None.
162. Maxwell DS, Pal A, Z-H P, Shavrin A, Faderl S, Harris D, Van Q, Liu Z, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM, Estrov Z, Bornmann WG. Structure-based drug design of c-kit inhibitors for use in the treatment of acute myeloid leukemia. Blood 108(11):1906a, 2006. PMID: None.
163. Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Ravandi-Kashani F, Cortes J, Giles F, Andreeff M, Koller CA, Lerner S, Kantarjian HM, Keating MJ. The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R)(OFAR) in patients with Richter's transformation and FLU-refractory CLL. J Clin Oncol 24(18S), 2006. PMID: None.
164. Alatrash G, Keating MJ, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian HM, Lerner S, Wierda WB. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with fludarabine (F), cyclophosphamide (C), and rituximab (FCR). Blood 108(11):2330a, 2006. PMID: None.
165. Tam CS, Otero-Palacios J, Lerner S, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, O'Brien S, Keating MJ. CD20 antigen expression is increased in trisomy 12 CLL as compared to other cytogenetic subtypes. Blood 108(11):4939b, 2006. PMID: None.
166. Faderl S, Ferrajoli A, Wierda W, Ravandi F, Estrov Z, Verstovsek S, Thomas DA, Garcia-Manero G, Kwari M, Kantarjian HM. Clofarabine combinations in acute myeloid leukemia (AML) salvage: a dose-finding phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C). Blood 106(11):2803a, 2005. PMID: None.
167. O'Brien S, Wierda WG, Faderl S, Ferrajoli A, Bueso-Ramos CE, Browning M, Kantarjian H. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood 106(11):2117a, 2005. PMID: None.
168. Wang XS, Ferrajoli A, Broadway JB, Mobley GM, Mendoza TR, Keating MJ, Cleeland C. Symptom assessment in patients with chronic lymphocytic leukemia: validation and application of the M.D. Anderson symptom inventory. Blood 106(11):5000b, 2005. PMID: None.
169. Ravandi-Kashani F, Kantarjian H, Verstovsek S, Ferrajoli A, Wierda W, Odinga S, Huang X, Pierce S, Faderl S, Giles F, O'Brien S, Keating M. Combined therapy with alemtuzumab and pentostatin is feasible and effective in T-lymphoproliferative disorders. Blood 106(11):5024b, 2005. PMID: None.
170. Ferrajoli A. Complete eradication of minimal residual disease (MRD) in patients with hairy cell leukemia (HCL) afer cladribine (2CDA) followed by an extended course of rituximab. Blood 106(11):3258a, 2005. PMID: None.
171. Motta M, Wierda W, O'Brien S, Faderl S, Ferrajoli A, Detry M, Lerner S, Kantarjian H, Keating M. Infections in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy. Blood 106(11):720a, 2005. PMID: None.
172. Wierda WG, O'Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, Cortes J, Thomas D, Ravandi F, Garcia-Manero G, Andreeff M, Lerner S, Kantarjian H, Keating M. Salvage therapy with combined cyclophosphamide(C), fludarabine (F), alemtuzumab (A), and rituximab (R)(CFAR) for heavily pre-treated patients with CLL. Blood 106(11):719a, 2005. PMID: None.
173. Yee KWL, Cortes J, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda WG, Thomas D, Faderl S, King I, O'Brien SM, Sznol M, Giles FJ. Phase I study of Triapine(R) and cytarabine (afa-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS). Blood 106(11):4925b, 2005. PMID: None.
174. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks STAT3 and STAT5 phosphorylation, inhibits proliferation, and induces apoptosis in acute myeloid leukemia (AML) but not normal cells. Blood 106(11):2462a, 2005. PMID: None.
175. Thomas DA, Cortes J, O'Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau S, Keating M, Andreeff M, Kantarjian H. Update of the modified Hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 106(11):1831a, 2005. PMID: None.
176. Ferrajoli A, Faderl S, Wang T, Priebe W, Kantarjian H, Talpaz M, Estrov Z. WP1066: a novel P1-3K inhibitor with antileukemic activity in Philadelphia chromosome-positive ALL. Blood 106(11):850a, 2005. PMID: None.
177. Faderl S, Ravandi F, Ferrajoli A, Garcia-Manero G, Estrov Z, Thomas DA, O'Brien S, Verstovsek S, Wierda W, Cortes J, Giles FJ, Kwari M, Jarmon R, Kantarjian HM. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) >60 years with newly diagnosed acute myeloid leukemia (AML). Blood 106(11):2804a, 2005. PMID: None.
178. Faderl, S, Ravandi-Kashani F, Ferrajoli A, Estrov Z, Wierda W, Verstovsek S, Garcia-Manero G, Estey E, Kwari M, Kantarjian HM. Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) > 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 23:6627, 2005. PMID: None.
179. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O'Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, J-P I, Frankel SR, Richon V, Fine B, Kantarjian H. Final results of a Phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. Blood 106(11):2801a, 2005. PMID: None.
180. A-M T, Keating MJ, McLaughlin P, O'Brien S, Wierda W, Ferrajoli A, Manning J, Kantarjian H. Comparison of small lymphocytic lymphoma with chronic lymphocytic leukemia. Blood 106(11):921a, 2005. PMID: None.
181. Freireich, EJ, Kantarjian H, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II study of EL625, a p53 antisense oligonucleotide, and chemotherapy in refractory and relapsed acute myelogenous leukemia (AML). . J Clin Oncol 23(16S):6617, 2005. PMID: None.
182. Faderl S, Ferrajoli A, Wierda W, Ravandi F, O'Brien S, Garcia-Manero G, Thomas DA, Browning ML, Keating MJ. Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 106(11):2963a, 2005. PMID: None.
183. Wierda, WG, O’Brien SM, Wang X, Ferrajoli A, Faderl SH, Ravandi-Kashani F, K-A D, Kantarjian H, Lerner S, Keating MJ. Models predictive for survival in untreated patients with CLL at initial presentation and initial treatment. . J Clin Oncol 23(16S):6593, 2005. PMID: None.
184. Aribi A, Keating M, O'Brien S, Ferrajoli A, Faderl S, Lerner S, Koller C, Wierda W, Cortes J, Kantarjian H, Ravandi-Kashani F. Long-term follow-up of patients with T-large granular lymphocyte leukemia (T-LGL): experience in a single institution. Blood 5026b, 2005. PMID: None.
185. Estey, EH, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H. Use of all-transretinoic acid (ATRA) + arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia (APL). . Blood 104(11):393a, 2004. PMID: None.
186. Verstovsek, S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Beran M, Talpaz M, Kantarjian H. PEG-Intron for myeloproliferative diseases: An update of ongoing phase II study. . Blood 104(11):1517a, 2004. PMID: None.
187. Ravandi-Kashani, F, O’Brien S, Lerner S, Ferrajoli A, Wierda W, Giles F, Herling M, Jones D, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: 17-year experience at a single institution. . Proc Amer Soc Clin Oncol 23:6570, 2004. PMID: None.
188. Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-Manero G, Koller C, O’Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W, Kantarjian HM. Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) > age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). . Blood 104(11):875a, 2004. PMID: None.
189. Thomas, DA, Garcia-Manero G, Faderl S, O’Brien S, Giles FJ, Ferrajoli A, Wierda W, Verstovsek S, Cortes J, Kantarjian H. Preliminary results of phase I trial of sphingosomal vincristine (SV) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL). Blood 104(11):2735a, 2004. PMID: None.
190. Ferrajoli, A, Faderl S, Van Q, Harris DM, Priebe W, Kantarjian HM, Talpaz M, Estrov E. WP-1066, a next generation member of JAK-Stat inhibitors, induces cell cycle arrest, abrogates proliferation, and induces apoptosis of acute myeloid leukemia (AML) cells. Blood 104(11):1169a, 2004. PMID: None.
191. Thomas, DA, Cortes J, O’Brien SM, Giles F, Faderl S, Verstovsek S, Ferrajoli A, Beran M, Cabanillas F, Kantarjian H. Favorable outcome with hyper-CVAD in lymphoblastic lymphoma (LL). . Proc Amer Soc Clin Oncol 23:6597, 2004. PMID: None.
192. Cortes, J, O’Brien S, Verstovsek S, Daley G, Koller C, Ferrajoli A, Pate O, Faderl S, Ravandi-Kashani F, Talpaz M, Zhu Y, Statkevich P, Sugrue M, Kantarjian H. Phase I study of Lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib. . Blood 104(11):1009a, 2004. PMID: None.
193. Cortes, J, Garcia-Manero G, O’Brien S, Hernandez I, Rackoff W, Faderl S, Thomas D, Ferrajoli A, Talpaz M, Kantarjian H. A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy. Blood 104(11):1011a, 2004. PMID: None.
194. O’Brien, S, Thomas D, Cortes J, Faderl S, Giles F, Pierce S, Shan J, Ferrajoli A, Keating M, Kantarjian H. Long-term follow-up results of hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). . Proc Amer Soc Clin Oncol 23:6539, 2004. PMID: None.
195. Faderl, S, Ferrajoli A, Wierda W, Verstovsek S, Ravandi-Kashani F, Garcia-Manero G, Estey E, Thomas DA, Kornblau S, Kwari M, Gandhi V, Kantarjian HM. Phase I study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine (ARA-C) in patients (pts) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML). . Blood 104(11):1809a, 2004. PMID: None.
196. Wierda, W, Faderl S, O’Brien S, Cortes J, Ferrajoli A, Giles F, Andreeff M, Koller C, Kantarjian H, Keating M. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104(11):340a, 2004. PMID: None.
197. Faderl, S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-Stat inhibitor, has proapoptotic and antileukemic activity in acute myeloid leukemia (AML) cell lines and AML patients samples. Blood 104(11):2528a, 2004. PMID: None.
198. Schlette, E, Ferrajoli A, Lerner S, Lai R, Medeiros LJ, Keating MJ. Clinicopathologic features of CLL with trisomy 12: an aggressive disease regardless of atypical morphology, atypical immunophenotype or additional chromosomal abnormalities. Leuk & Lymph 44:67, 2003. PMID: None.
199. Ferrajoli, A, Keating MJ, Van Q, Harris DM, Donato NJ, Priebe W, Kantarjian HM, Talpaz M, Levitzki A, Estrov Z. The protein kinase inhibitor AG1801 abrogates constitutive STAT3 phosphorylation, suppresses colony-forming cell proliferation, and activates the apoptotic pathway in chronic lymphocytic leukemia (CLL). Blood 102:810a, 2003. PMID: None.
200. FerrajoliA, O’Brien S, Lerner S, Wierda W, Faderl S, Keating MJ. Chronic lymphocytic leukemia in the elderly, outcome of patients age 70 and older. Leuk & Lymph 44:73, 2003. PMID: None.
201. Faderl, S, Albitar M, Wierda W, Ferrajoli A, Manshouri T, Garcia-Manero G, O’Brien S, Thomas DA, Kantarjian HM, Browning ML, Keating MJ. Continuous I.V. infusion (C.I.) followed by subcutaneous (S.C.) alemtuzumab plus rituximab is active in patients with relapsed/refractory chronic lymphoproliferative disorders (LPD). Blood 102:2505a, 2003. PMID: None.
202. Giles, F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O’Brien S, Beran M, Estey EH. Adaptive randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myelogenous leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Blood 102:4740b, 2003. PMID: None.
203. Ossa, G, Hennessy B, Cortes J, Giles F, Medina J, Ferrajoli A, Garcia-Manero G, Faderl S, O’Brien S, Kantarjian H, Verstovsek S. Systemic mastocytosis: A review of M.D. Anderson experience. Blood 102:5100b, 2003. PMID: None.
204. Verstovsek, S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Koller C, Beran M, Talpaz M, Freireich EJ, Kantarjian H. PEG intron therapy for patients with myeloproliferative diseases (MPD): Interim analysis of phase II study. . Blood 102:3421a, 2003. PMID: None.
205. O’Brien, SM, Gribben JG, Thomas DA, Albitar M, Wierda W, Ferrajoli A, Lerner S, Kantarjian HM, Kipps T, Keating MJ. Alemtuzumab for minimal residual disease in CLL. Blood 102:371a, 2003. PMID: None.
206. Jilani, I, O’Brien S, Kantarjian H, Caiyo J, Giles F, Ferrajoli A, Keating M, Albitar M. CD23 quantification in chronic lymphocytic leukemia on the effects of anti-CD23 therapy on its levels. Blood 102:5170b, 2003. PMID: None.
207. Wierda, W, O’Brien S, Faderl S, Ferrajoli A, Lerner S, Wang X, Thomas D, Garcia-Manero G, Cortes, J, Kantarjian H, Keating M. Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. . Blood 102:373a, 2003. PMID: None.
208. Liu, NS, Keating MJ, Albitar M, Wierda WG, Ferrajoli A, Tran N, Lerner S, Kantarjian HM, O’Brien S. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. Blood 102:2498a, 2003. PMID: None.
209. Wierda, W, O’Brien S, Ferrajoli A, Faderl S, Kornblau SM, Andreeff M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H, Keating M. Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL. . Blood 102:5167b, 2003. PMID: None.
210. Cortes, J, O’Brien S, Talpaz M, Luthra R, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Ferrajoli A, Wierda W, Thomas D, Faderl S, Kantarjian H. Clinical significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate (Gleevec) therapy: Low levels of residual disease predict for response duration. Blood 102:1513a, 2003. PMID: None.
211. Giles, F, Cortes J, Thomas D, Verstovsek S, Garcia-Manero G, Faderl S, Ferrajoli A, Hagey A, Gordon G, Kantarjian H. Phase I study of ABT-751, a novel tubulin-binding agent, in patients with refractory hematological malignancies. . Blood 102:4735b, 2003. PMID: None.
212. Jilani, I, O’Brien S, Kantarjian H, Caiyo J, Giles F, Ferrajoli A, Keating M, Albitar M. Quantitative measurement of CD52 on the surface of CLL cells before and after treatment with alemtuzumab. Blood 102:5171b, 2003. PMID: None.
213. Cortes, J, O’Brien S, Ferrajoli A, Daley GQ, Pate O, Verstovsek S, Faderl S, Zhu Y, Sugrue M, Statkevich P, Talpaz M, Kantarjian H. Phase I study of a imatinib and lonafarnib (SCH66336) in patients (pts) with chronic myeloid leukemia (CML) refractory to imatinib mesylate. Blood 102:3382a, 2003. PMID: None.
214. Ferrajoli, A, Thomas DA, Albitar M, Lerner S, Kantarjian HM, Keating MJ, O’Brien SM. Alemtuzumab for minimal residual disease in CLL. Proc. Amer Soc Clin Oncol 22:2290, 2003. PMID: None.
215. Estey, EH, Faderl S, Giles F, Thomas D, Ferrajoli A, Wierda W, Verstovsek S, Garcia-Manero G, Kantarjian HM. All-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL. . Blood 102:2283a, 2003. PMID: None.
216. Cortes, JE, Talpaz M, O’Brien S, Giles F, Garcia-Manero G, Rios MB, Thomas D, Ferrajoli A, Verstovsek S, Faderl S, Letvak L, Bochinski K, Kantarjian H. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with Imatinib at 400 mg or 800 mg daily. Blood 100:350a, 2002. PMID: None.
217. El-Zimaity, MT, Kantarjian HM, Talpaz M, Garcia-Manero G, O’Brien S, Giles FJ, Verstovsek S, Ferrajoli A, Rios MB, Hayes KH, Cortes JE. Response to imatinib in patients with chronic myeloid leukemia (CML) with variant Philadelphia chromosome (Ph). Blood 100:3114a, 2002. PMID: None.
218. Giles, F, Estey E, Cortes J, Thomas D, Ferrajoli A, Faderl S, Verstovsek S, Wathen K, O’Brien S, Kantarjian H. Adaptively randomized prospective study of troxacitabine and ara-C (A), troxacitabine and idarubicin (I), and IA in older patients with unfavorable karyotype AML. Blood 100:2214a, 2002. PMID: None.
219. Cortes, JE, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kantarjian H. Treatment of hypereosinophilic syndrome (HES) with imatinib mesylate. Blood 100:257a, 2002. PMID: None.
220. Faderl, S, Thomas DA, O’Brien S, Wierda W, Kantarjian HM, Garcia-Manero G, Giles FJ, Koller CA, Beran M, Ferrajoli A, Lerner S, Keating MJ. Combined use of alemtuzumab and rituximab inn patients with relapsed and refractory chronic lymphoid malignancies – An update of the M.D. Anderson Experience. Blood 100:775a, 2002. PMID: None.
221. Bueso-Ramos, C, Ferrajoli A, Keating MJ, Estrov Z. Aberrant cytokinesis, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Blood 100:4955b, 2002. PMID: None.
222. Ferrajoli, A, O’Brien S, Williams ML, Faderl S, Kantarjian H, Keating MJ. Campath-1H in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients. Blood 98:1541a, 2001. PMID: None.
223. Ferrajoli, A, Keating MJ, Manshouri T, Days A, Estrov Z, Giles F, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O’Brien S, Albitar M. TNF-alpha, a novel prognostic factor for survival in chronic lymphocytic leukemia. Blood 98:1503a, 2001. PMID: None.
224. Ferrajoli, A, M-S L, Keating M, O’Brien S, Kantarjian H, Talpaz M, Estrov Z. Interleukin-7 (IL-7) stimulates Chronic Lymphocytic Leukemia (CLL) colony-forming cell proliferation. . Blood 96:3242a, 2000. PMID: None.
225. Ferrajoli, A, O’Brien S, Kurzrock R, Giles F, Williams M, Thomas D, Kantarjian H, Beran M, Keating M. Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD52. J Clin Oncol:22a, 2000. PMID: None.
226. Ferrajoli, A, Estrov Z, Keating M, Lerner S, Manshouri T, Beran M, Kantarjian H, Albitar M. The levels of vascular endothelial growth factor receptor-2 in peripheral blood chronic lymphocytic leukemia (CLL) cells correlates with patient survival. Blood 94:2396a, 1999. PMID: None.
227. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey E, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. . Blood 88:94a, 1996. PMID: None.
228. Saglio, G, Gottardi E, Parziale A, De Micheli D, Liberati AM, Ferrajoli A, Pane F, Salvatore F, Guerrasio A. Mechanisms of action of interferons. Haematologica 79:1, 1994. PMID: None.
229. Liberati, AM, Garofani G, Schippa M, Di Clemente F, Cinieri S, Mancini S, Adiuto D, Ferrajoli A. Biological activities of GM-CSF given after high dose chemotherapy. Ann Oncol 5:141, 1994. PMID: None.
230. Liberati, AM, Garofani P, Schippa M, Di Clemente F, Cinieri S, Ferrajoli A. A phase II study on high-dose chemotherapy and GM-CSF in hematological malignancies. La Revista de Investigation Clinica 4:323, 1994. PMID: None.
231. Liberati, AM, Schippa M, Garofani P, Cinieri S, Mancini S, Di Clemente F, Ferrajoli A, Tognellini R, Caputo F, Zuccaccia M. Comparison of haematopoietic precursor mobilization after high dose carboplatinum and cyclophosphamide. Br J Haematol 87:611, 1994. PMID: None.
232. Rozovski U, Li P, Harris D, Liu Z, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda WG. STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.XViw CLL 2013 Conference. None. PMID: None.
233. Burger J, Li K, Keating M, Sivina M, Ferrajoli A, Jalayer A, Huang X, Kantarjian H, Wierda W, O'Brien S, Hellerstein M, Turner S, Emson C, Chen S, Yan X, Chiorazzi N. Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma. 56th Annual ASH Meeting, 2014. None. PMID: None.
234. Rozovski U, Calin G, Tetsirp S, Abundu L, Harris D, Ping L, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger J, O’Brien S. Signal transducer and activator of transcription (STAT)-3 regulates and deregulates microRNA expression in. XViw CLL 2013 Conference. None. PMID: None.
235. Jain P, Trinh L, Wang X, Benjamini O, Lerner S, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, O’Brien S, Wierda WG. Deletion 11q abnormality in patients with chronic lymphocytic leukemia (CLL) may not have adverse outcomes. XViw CLL 2013 Conference. None. PMID: None.
236. Takahashi K, Kantarjian H, Jain P, Jabbour E, Wierda W, Pemmaraju N, Ferrajoli A, Dellasala S, Pierce S, Verstovsek S, Ravandi F, O'Brien S, Cortes JE. Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase. 56th Annual ASH Meeting, 2014. None. PMID: None.
237. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D'Arena G, Murru R, Vincelli DI, Reda G, Vitale C, Ferrajoli A, Laurenti L. Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia. None. PMID: None.
238. Thompson P, Keating M, Hinojosa C, Smith S, Daver N, Jain N, Burger J, Estrov Z, O'Brien S, Wierda W, Kantarjian H, Ferrajoli A. Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study . 56th Annual ASH Meeting, 2014. None. PMID: None.
239. Ferrajoli A. Lenalidomide-based Regimens in Salvage and Frontline Therapy of CLL. None. PMID: None.
240. Strati P, Keating MJ, O’Brien S, Ferrajoli A, Burger J, Faderl S, Jain N, Wierda WG. Karyotype influences response to frontline treatment in chronic lymphocytic leukemia with deletion 17p. XViw CLL 2013 Conference. None. PMID: None.
241. Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger J, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris R, Pemmaraju N, Daver N, MD, Jain N, Cortes J, Kantarjian H. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL) . 56th Annual ASH Meeting, 2014. None. PMID: None.
242. Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, Estrov Z, Jorgensen J, Faderl SH, Wierda WG. Early bone marrow MRD negativity with first-line FCR in CLL may prompt consideration of stopping treatment. XViw CLL 2013 Conference. None. PMID: None.
243. Falchi L, Keating M, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda W, Ferrajoli A. Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance. 56th Annual ASH Meeting, 2014. None. PMID: None.
244. Strati P, Keating MK, O'Brien SM, Ferrajoli A, Burger JA, Jain N, Estrov Z, Jorgensen J, Faderl S, Wierda WG. Achieving bone marrow CLL minimal residual disease-free status with first-line FCR is associated with improved PFS and can be considered a primary treatment objective. Haematologica. PMID: None.
245. Thompson P, Wierda W, Ferrajoli A, Smith S, O'Brien S, Burger J, Estrov Z, Jain N, Kantarjian H, Keating M. Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens. 56th Annual ASH Meeting, 2014. None. PMID: None.
246. Hwang J, Suarez-Almazor ME, Cantor SB, Barbo AG, Lin HY, Ahmed S, Gregor MC, Donato-Santana C, Eng C, Ferrajoli A, Fisch M, McLaughlin P, Simon GR, Rondon G, Shpall EJ, F Lok AS. Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. 2017 ASCO Annual Meeting (Oral presentation). Journal of Clinical Oncology. PMID: None.
247. Falchi L, Keating MK, Wang X, Schlette EJ, Sargent RL, Marom EM, Truong M, Wierda WG, Ferrajoli A. Predictors of survival in patients with transformed chronic lymphocytic leukemia (TC). Journal of Clinical Oncology. PMID: None.
248. Kim E, Werner L, Keating M, Wierda W, Ferrajoli A, Estrov Z, Zacharian G, Kipps T, Kantarjian H, Neuberg D, O'Brien S, Burger JA. Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia. 56th Annual ASH Meeting, 2014. None. PMID: None.
249. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Faderl S, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (dell7p). Journal of Clinical Oncology. PMID: None.
250. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris D, Li P, Liu Z, Yuan Wu JI, Wierda W, Burger JA, O'Brien S, Jain N, Ferrajoli A, Keating M, Estrov Z. STAT3-Driven, Aberrantly Expressed Lipoprotein Lipase Mediates Free Fatty Acid Metabolism in Chronic Lymphocytic Leukemia Cells. 56th Annual ASH Meeting, 2014. None. PMID: None.
251. Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda W, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian H. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). 56th Annual ASH Meeting, 2014. None. PMID: None.
252. Jain P, Kantarjian H, Jabbour E, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes JE. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). 56th Annual ASH Meeting. None. PMID: None.
253. Ravandi F, Jeffrey J, Thomas DA, O'Brien S, Jabbour E, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Kadia T, Jain N, Wang SA, Kebriae P, Champlin RE, Estrov Z, Cortes JE, Kantarjian H. Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). 56th Annual ASH Meeting, 2014. None. PMID: None.

Book Chapters

1. W-G T, Ferrajoli A. Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation. In: Leukemias: Principles and Practice of Therapy. None. Wiley-Blackwell, 327-337, 2010.
2. Ferrajoli A. Treatment of Younger Patients with Chronic Lymphocytic Leukemia. In: Hematology 2010. 30. American Society of Hematology (ASH), 82-89, 2010.
3. Ding W, Ferrajoli A. Evidence-Based Mini-Review: The role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. In: Hematology Am Soc Hematol Educ Program. 30. American Society of Hematology (ASH), 90-92, 2010.
4. Ferrajoli, A, Keating MJ, O’Brien S. Chemotherapy of Chronic Lymphocytic Leukemia. In: Chronic Lymphocytic Leukemia Molecular Genetics, Biology, Diagnosis, and Management. None. Humana Press, 241-254, 2004.
5. Estrov Z, Ferrajoli A, Wetzler M, Kurzrock R, Talpaz M. Interruption of Autocrine Growth Factor Loops: A New Approach in leukemia therapy. In: Challenges of Modern Medicine. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma. None. Raven Press, 185-188, 1994.